Stockwinners Market Radar for February 26, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EST Cathie Wood's ARK Investment bought 157K shares of 10x Genomics today

19:50 EST Treasure Global Inc trading halted, news pending

19:50 EST Phunware trading halted, news pending

19:12 EST Dutch Bros chairman sells $26.6M in common stock - In a regulatory filing, Dutch Bros disclosed that its Executive Chairman Travis Boersma sold 941K shares of common stock on February 22nd as part of an option exercise in a total transaction size of $26.6M.

19:00 EST Quanterix reschedules Q4 call, reaffirms 2023 guidance - Quanterix announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such results with the filing of its Annual Report on Form 10-K for the year ended December 31, 2023, the deadline for which is February 29, 2024. The investor call will now be held on Thursday, February 29, 2024. Quanterix expects 2023 revenue, gross margin and cash usage to be in line with guidance provided on January 10, 2024. Quanterix expects to issue a press release regarding its fourth quarter 2023 and full year 2023 financial results prior to the conference call.

18:42 EST Roku exec Collier sells 12,277 class A shares - In a regulatory filing, Roku exec Charlies Collier disclosed the sale of 12,277 class A common shares of the company on February 22 at a price of $65.06 per share.

17:48 EST Meta activates dedicated team to counter disinformation, AI abuse in EU election - "Meta has been preparing for the EU Parliament elections for a long time. Last year, we activated a dedicated team to develop a tailored approach to help preserve the integrity of these elections on our platforms...These lessons help us focus our teams, technologies, and investments so they will have the greatest impact...Over the last eight years, we've rolled out industry-leading transparency tools for ads about social issues, elections or politics, developed comprehensive policies to prevent election interference and voter fraud, and built the largest third party fact-checking program of any social media platform to help combat the spread of misinformation. More recently, we have committed to taking a responsible approach to new technologies like GenAI. We'll be drawing on all of these resources in the run-up to the election. As the election approaches, we'll also activate an EU-specific Elections Operations Center, bringing together experts from across the company from our intelligence, data science, engineering, research, operations, content policy and legal teams to identify potential threats and put specific mitigations in place across our apps and technologies in real time...," said Meta Platforms in part, in an earlier blog posting. Reference Link

17:40 EST Unity says 2023 comparable base starts with $1.7B in revenue, $274M in EBITDA - Says had this onetime gain from wet foreign exchange. Says showed that at $99M in revenue, for example. Says had a $102M benefit in EBITDA. Says you have to take that into account because that's a onetime gain. Says portfolio changes were $283M in 2023. Says most of that is in growth, a small portion to be precise, EUR 15M is within growth, which is the Luna business. Says have to take that into account that operated at a significant loss, which is why the company is exiting these businesses because it could not create a return. Says did not quantify that because it's not audited, but it's a very significant number. Says customer credits which was $72M in revenue and $72M in EBITDA at so if you really look at the comparable base for 2023, you should start with $1.7B in revenue and $274M in EBITDA. Comments taken from Q4 earnings conference call.

17:24 EST Ellington Financial says will recommend to cut monthly dividend to 13c from 15c - CEO Laurence Penn stated: "Our adjusted distributable earnings did drop during the quarter, but it should recover as Longbridge continues to build back towards profitability, as we work out a few nonperforming commercial mortgage loans and REO assets, and as we continue to deploy new capital and rotate capital into higher-yielding sectors. That said, management expects to recommend to the board a reduction of the monthly dividend from $0.15 to $0.13 per share, beginning in March. Notably, this is just $0.01 below the $0.14 per share monthly dividend level we set five years ago, when we first shifted from a quarterly to a monthly dividend. Looking ahead, our diversified capital base now includes the common equity, low-cost preferred equity and unsecured debt added through the merger. This diversified capital base, together with our ample liquidity and additional untapped borrowing capacity, should allow us to capitalize on the many attractive investment opportunities we are seeing, including high-yielding lending opportunities in our proprietary loan pipelines and distressed situations in commercial real estate debt."

16:58 EST Janux Therapeutics up 95% at $29.47 after updates on its clinical data - Shares of Janux Therapeutics are up 95% at $29.47 after the company presented "encouraging" safety and efficacy Data in ongoing dose escalation trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors . The company stated: "JANX007 is in a Phase 1a clinical trial in subjects with advanced or metastatic prostate cancer (mCRPC). The subjects enrolled in the trial were heavily pre-treated with a median of 4+ lines of therapy. As of February 12, 2024, 23 subjects were treated with JANX007 in the dose escalation portion of the Phase 1a clinical trial. An increasing depth of PSA declines and RECIST responses at higher doses were observed, while a favorable safety profile was maintained. At a starting dose greater than or equal to 0.1 mg, 14 of 18 (78%) subjects achieved PSA30 declines and 10 of 18 (56%) subjects achieved PSA50 declines. At a starting step dose of greater than or equal to 0.2 mg, 6 of 6 (100%) subjects achieved PSA30 declines and 5 of 6 (83%) subjects achieved PSA50 declines. Initial step doses of JANX007 greater than or equal to 0.2 mg drove deeper and more durable PSA responses, including one subject that achieved a PSA90 decline. Cytokine Release Syndrome (CRS) was observed to be temporary and mild, presenting only as low-grade 1 or 2 events, and was quickly managed with treatment. These incidents of CRS were mainly reported during the first treatment cycle, with no subsequent occurrences in later cycles. Similarly, the majority of treatment-related adverse events (TRAEs) not associated with CRS were of low severity (Grade 1 or 2) and also primarily occurred in the initial cycle. There was a low incidence of Grade 3 TRAEs, and no Grade 4 or 5 events were observed. JANX007 has been administered at doses up to 3mg, significantly exceeding the anticipated maximum tolerable dose for the parental T cell engager, while the maximum tolerable dose for the TRACTr has not yet been established. Based on this safety profile, we are continuing dose optimization for JANX007 with the goal of further deepening PSA responses, while maintaining a favorable safety profile. Janux anticipates providing an update on doses for expansion in the second half of 2024. JANX008 is in a Phase 1a clinical trial in subjects with advanced or metastatic solid tumors known to express high levels of the EGFR target, including colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). As of February 12, 2024, 11 heavily pre-treated, late-stage subjects across all four tumor types have been enrolled. Encouraging signs of clinical activity were observed, while a favorable safety profile was maintained. In one subject with NSCLC treated with JANX008 at 0.15mg once-weekly, a confirmed partial response (PR) by RECIST criteria with 100% reduction of the target lung lesion and elimination of liver metastasis with no CRS or TRAEs has been observed. This subject remains on treatment and their PR has been maintained through their week-18 scan. One subject with RCC experienced a 12% reduction in the size of a large RCC mass and significant clinical benefit with Grade 1 CRS. The early safety profile for JANX008 is consistent with the TRACTr design principles of tumor-specific activation while avoiding healthy tissue toxicity with a broadly expressed target. In the 11 subjects enrolled at doses up to 1.25mg, which is significantly above the projected maximum tolerable dose of the parental T cell engager, Grade 1 CRS was observed in only two subjects and no Grade 2 or higher CRS was seen. The majority of non-CRS TRAEs were also low-Grade 1 or 2 and occurred predominantly in cycle one. No treatment related serious adverse events or dose-limiting toxicities have been observed. Based on this safety profile, we are continuing in the dose escalation and optimization portion of the trial for JANX008."

16:53 EST Chevron, Hess in talks with Exxon, CNOOC over right of first refusal provision - In a regulatory filing, Chevron (CVX) said that it may not complete the acquisition of Hess Corporation (HES) within the time frame the company anticipates or at all, which could have adverse effects on Chevron. The completion of the acquisition of Hess Corporation is subject to a number of conditions, including regulatory approvals and approval by Hess stockholders of the adoption of the merger agreement. Additionally, Hess and Chevron have been engaged in discussions with Exxon Mobil Corporation (XOM) and China National Offshore Oil Corporation, or CNOOC, regarding a right of first refusal provision in the joint operating agreement for the Stabroek Block offshore Guyana. If these discussions do not result in an acceptable resolution and arbitration (if pursued) does not result in a confirmation that such right of first refusal provision is inapplicable to the merger, then there would be a failure of a closing condition under the Merger Agreement, in which case the merger would not close. For additional information, please see the section entitled "The Merger-Stabroek JOA" in Chevron's preliminary registration statement on Form S-4 to be filed on February 26, 2024. Further, on December 7, 2023, Chevron and Hess each received a request for additional information and documentary materials (Second Request) from the Federal Trade Commission (FTC) in connection with the FTC's review of the merger. Issuance of the Second Request extends the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, until 30 days after Chevron and Hess have substantially complied with the Second Request, unless that period is extended voluntarily by Chevron and Hess or terminated sooner by the FTC.

16:38 EST CRH to acquire Adbri in Australia - CRH and Adbri have entered into a binding agreement under which CRH will acquire the remaining 57% of the ordinary shares of Adbri not owned by Barro for the previously agreed cash consideration of A$3.20 per share. The Offer values Adbri at an equity valuation of A$2.1B on a 100% basis and values the approximately 53% of issued share capital that the Partners do not currently have an interest in and which CRH has agreed to acquire at A$1.1B. Albert Manifold, Chief Executive of CRH, said: "We are pleased to reach this important milestone in the potential acquisition of Adbri in partnership with the Barro family. Adbri is an attractive business with high-quality assets and leading market positions that complement our core competencies in cement, concrete and aggregates while creating additional opportunities for growth and development for our existing Australian business. We look forward to working with the Barro family over the coming years to enhance the long-term growth and performance of Adbri."

16:34 EST Wendy's names Matt Spessard as Chief Information Officer - The Wendy's Company announced the appointment of Matt Spessard as Chief Information Officer. He will report to President and Chief Executive Officer Kirk Tanner and serve on the Wendy's Senior Leadership Team. Spessard will succeed Kevin Vasconi who has served as Chief Information Officer since October 2020. Spessard has served as Senior Vice President, Global Chief Technology Officer for The Wendy's Company since August 2022.

16:32 EST American Electric announces CEO transition - American Electric Power announced that Benjamin Fowke III, a member of the company's board and the former chairman and CEO of Xcel Energy, has been appointed interim CEO and president, effective immediately. Fowke succeeds Julie Sloat. The board determined, based on discussions with Sloat, that it is time to identify a new CEO to lead the company's next chapter. This decision was not a result of any disagreement with Sloat regarding AEP's operations, policies or financial performance, and was not made for cause or related to any ethical or compliance concern.

16:31 EST Perrigo increases quarterly dividend 1% - Perrigo Company announces that its board has approved a 1% increase in the company's quarterly dividend to 27.6c per share, or $1.10 per share on an annual basis, up from 27.3c per share. This marks the 21st consecutive year Perrigo has increased its dividend. The cash dividend is payable on March 26 to shareholders of record on March 8.

16:29 EST Zoom Video jumps 12% to $70.75 after Q4 earnings beat, above-consensus guidance

16:19 EST Codexis, Roche in licensing deal for newly engineered double-sranded DNA Ligase - Codexis (CDXS) announced it has entered into an agreement with Roche for an exclusive, global license for the Company's newly engineered double-stranded DNA or dsDNA, ligase for next-generation sequencing (NGS) library preparation and the Company's EvoT4 DNA ligase. Under the terms of the deal, Codexis will receive upfront and technical milestone payments. This deal supersedes the prior exclusive license on the EvoT4(TM) DNA ligase. "This transaction is the latest example of our ongoing commitment to focusing on the core areas of our business where we have the biggest opportunity to create impact in the market," said Kevin Norrett, MBA, Chief Operating Officer of Codexis. "Since announcing our prioritized strategy last July, we've executed multiple deals to monetize our non-core assets with market-leading companies. We are excited to collaborate again with Roche on this novel, dsDNA ligase. As a leader in NGS technologies, Roche (RHHBY) continues to bring important kits to market that provide the sensitivity and specificity required for the next wave of innovative NGS applications. With Roche's technical ability and commercial reach, we now have the ability to maximize the potential of our dsDNA ligase."

16:18 EST Group 1 Automotive acquires two Lexus dealerships in California - Group 1 Automotive announced the acquisition of Newport Lexus and Tustin Lexus, two Lexus dealerships in Orange County, California. The dealerships are expected to generate $350M in annual revenues bringing 2024 year-to-date total acquired revenues for Group 1 to $850M, which follows $1.1B of acquired revenues in 2023.

16:16 EST Brinker announces CFO transition, new CIO - Brinker International announced updates to its executive leadership team, including the retirement of Joe Taylor, EVP and CFO, the appointment of Mika Ware as SVP and CFO, effective June 27, and the appointment of Chris Caldwell as SVP and Chief Information Officer, effective Feb. 26.

16:15 EST Workday reiterates FY25 subscription revenue guidance of $7.725B-$7.775B - "Our fourth quarter and full-year fiscal 2024 results reflect the momentum building across our key investment initiatives," said Zane Rowe, CFO, Workday. "We are reiterating our fiscal year 2025 subscription revenue guidance of $7.725 billion to $7.775 billion, representing growth of 17% to 18%. We expect fiscal year 2025 non-GAAP operating margin of approximately 24.5%. Our outlook contemplates incremental investments to support enduring growth, while at the same time calls for continued margin expansion as we scale and optimize the business."

16:11 EST Janux Therapeutics announced positive clinical data for both clinical programs - Janux Therapeutics announced positive updated clinical data for both of its clinical programs. Janux will host a virtual event today at 4:30 PM ET. "These clinical data show encouraging safety and efficacy with JANX007 in metastatic castration-resistant prostate cancer and with JANX008 in late-stage solid tumors. The clinical data provide compelling proof-of-concept for the TRACTr platform in a setting where many other approaches have failed due to material safety issues or lack of efficacy," said David Campbell, CEO of Janux Therapeutics. "Our TRACTr platform provides an entry point to multiple, large solid tumor indications that are intractable with conventional TCE approaches. We look forward to continuing to advance these clinical trials and expanding to additional TCE targets, as we look to fulfill our mission to meaningfully address the unmet medical needs for cancer patients, especially those with late-stage disease."

16:11 EST Envista announces planned CEO succession process - Envista Holdings Corporation announced that the board and CEO Amir Aghdaei are formally launching a process to determine a successor for CEO. The board has formed a search committee and retained an executive search firm to find qualified external candidates to lead the next phase of Envista. This process is expected to be completed this year. Aghdaei will remain president and CEO until his successor is appointed.

16:08 EST Walgreens Boots Alliance names Lanesha Minnix as Chief Legal Officer - Walgreens Boots Alliance named Lanesha Minnix the company's executive vice president and global chief legal officer. Minnix, most recently EVP, general counsel and corporate secretary for Ecolab, Inc., will assume her new role with WBA on April 15. Minnix, who will report to WBA CEO Tim Wentworth and serve on his Executive Committee, will oversee the company's global legal, compliance, corporate governance and corporate security functions.

16:03 EST Workday announces intent to acquire HiredScore - Workday has entered into a definitive agreement to acquire HiredScore. The combination of Workday Talent Management, Workday Skills Cloud, and HiredScore's Talent Orchestration solutions, will provide customers with a comprehensive, transparent, and intelligent talent acquisition and internal mobility offering, helping them better address their ever-evolving people needs. "People are at the heart of every organization, and investing in new and innovative ways to unlock the potential of talent is more important than ever," said Carl Eschenbach, CEO, Workday. "HiredScore is the perfect complement to our product portfolio as we look to provide AI solutions that deliver real business value for our customers. The combination of our AI technologies that keep humans at the center, along with a deep understanding of the workforce landscape, will help organizations thrive and move forever forward."

15:55 EST FTI Consulting director sells $3.25M in common stock - In a regulatory filing, FTI Consulting disclosed that its director Laureen Seeger sold 15K shares of common stock on February 23rd in a total transaction size of $3.25M.

15:36 EST Intuitive Machines sees controllers communicating with Odysseus until Tuesday - Intuitive Machines said in a series of tweets: "Odysseus continues to communicate with flight controllers in Nova Control from the lunar surface. After understanding the end-to-end communication requirements, Odysseus sent images from the lunar surface of its vertical descent to its Malapert A landing site, representing the furthest south any vehicle has been able to land on the Moon and establish communication with ground controllers. [...] Flight controllers intend to collect data until the lander's solar panels are no longer exposed to light. Based on Earth and Moon positioning, we believe flight controllers will continue to communicate with Odysseus until Tuesday morning." Reference Link

14:45 EST Arlo Technologies to update long-term financial targets during investor day - Arlo Technologies announced that during the webcast and conference call with investors and analysts to be held on Thursday, February 29, at 5:00 p.m. ET, the company will provide a slide presentation focused on a detailed strategic overview and update to its long-term financial outlook in addition to discussing fourth quarter and full year 2023 results. During the event, Arlo management will discuss the company's outlook for the first quarter and full year 2024, provide a comprehensive strategy review, and update its targets on key metrics associated with the development of a new long-range plan. The news release announcing the fourth quarter and full year 2023 results will be disseminated on February 29, after the market closes, the company noted.

13:45 EST BioMarin discloses receipt of subpoena from U.S. Department of Justice - In a regulatory filing, BioMarin stated: "We recently received a subpoena from the U.S. Department of Justice requesting that we produce certain documents regarding our sponsored testing programs relating to VIMIZIM and NAGLAZYME. We have produced documents in response to the subpoena and are cooperating fully, but there is no assurance that such sponsored testing programs, or our other operations or programs, will not be found to violate such laws." Reference Link

13:01 EST Deswell Industries board elects Wai Ming Lau as chairman - Deswell Industries Board of Directors has unanimously elected Ms. Lau Wai Ming as Chairman of the Board, effective February 19, 2024. Ms. Lau was elected to the Board of Directors by the Company's shareholders at the 2023 Annual Meeting of Shareholders on February 6, 2024. Prior to joining the Company, Ms. Lau was an Executive Director at PAG Consulting where she headed the firm's Global Human Capital operations.

12:54 EST Change Healthcare outage likely caused by ransomware group Blackcat - In an incident update regarding their recent outage, the UnitedHealth unit said that, "On February 21, Change Healthcare began experiencing a cyber security issue. Once they became aware of the outside threat, and in the interest of protecting their partners and patients, they took immediate action to disconnect their systems to prevent further impact. Their experts and third-party cybersecurity vendors are working closely with law enforcement to address the matter... As is usual in any cybersecurity incident, Change Healthcare is not providing much detail about the specifics of the attack. In a regulatory filing, UnitedHealth Group reported believing a 'nation-state associated threat actor' gained access to their information technology systems. It is now believed that this attack is related to the ALPHV/Blackcat Ransomware-as-a-Service. It is not known if any data was exfiltrated from affected technology systems, though forensic experts and law enforcement agencies have been engaged to determine the scope of the issue. Change Healthcare is using multiple approaches to restore services in a safe and secure manner. They have reported that they are focusing on systems directly impacting patient care first, such as those related to e-prescribing and imaging. They are acutely aware of the impact of delays on the revenue cycle and will bring those systems online as soon as possible. As of Sunday (2/25), they expect to have more information on a timeline for claims, ERA, and eligibility service restorations on Tuesday (2/27)."Reference Link

12:45 EST Disney urges vote for company board nominees, not those of Trian or Blackwells - Disney's board of directors sent a letter to shareholders detailing what it calls "the progress it has made and continues to make on its strategic priorities, delivering on the promises it made just over one year ago." The board stated in part: "The board has been laser-focused on a strategy that will drive shareholder value. The company has restored its cash dividend and subsequently increased the dividend payment declared for July 2024 by 50%. Disney is also targeting $3 billion in share buybacks for FY24. As shared in its first quarter earnings, the company has also made great strides in reigning in costs and is on track to meet or exceed its cost cutting target of $7.5 billion by the end of FY24. Disney also reaffirmed it is on track to deliver $8 billion in free cash flow, and to reach profitability in its combined DTC streaming businesses in Q4 FY24. Disney's creative engines continue to be recognized with numerous nominations across the TV and film industry... Disney's board of directors believes all of its 12 nominees are uniquely qualified to continue this important progress and create long-term shareholder value. The board urges shareholders to protect their investment and the future of the company by voting the White proxy card for only Disney's 12 nominees now and not the Trian Group or Blackwells nominees. The 2024 Annual Meeting of Shareholders will be held on April 3, 2024. The Disney board of directors does not endorse the Trian Group nominees, Nelson Peltz and Jay Rasulo, or the Blackwells nominees, Craig Hatkoff, Jessica Schell and Leah Solivan, and believes that they are unqualified to serve on Disney's Board and preserve value creation for shareholders in this increasingly complex global landscape." Reference Link

12:35 EST Bandai Namco's 'Tekken 8' has sold 2M units globally - Bandai Namco said that "Tekken 8," which released in January, has already achieved 2M units sold globally. Reference Link

12:12 EST JPMorgan CEO: Some of the smaller banks should be allowed to merge

12:04 EST FTC challenges Kroger's acquisition of Albertsons - The Federal Trade Commission has sued to block Kroger Company's (KR) $24.6B acquisition of the Albertsons Companies (ACI), alleging that the deal is anticompetitive. The FTC charges that the proposed deal will eliminate fierce competition between Kroger and Albertsons, leading to higher prices for groceries and other essential household items for millions of Americans. The loss of competition will also lead to lower quality products and services, while also narrowing consumers' choices for where to shop for groceries. For thousands of grocery store workers, Kroger's proposed acquisition of Albertsons would immediately erase aggressive competition for workers, threatening the ability of employees to secure higher wages, better benefits, and improved working conditions. "This supermarket mega merger comes as American consumers have seen the cost of groceries rise steadily over the past few years. Kroger's acquisition of Albertsons would lead to additional grocery price hikes for everyday goods, further exacerbating the financial strain consumers across the country face today," said Henry Liu, Director of the FTC's Bureau of Competition. "Essential grocery store workers would also suffer under this deal, facing the threat of their wages dwindling, benefits diminishing, and their working conditions deteriorating." The FTC issued an administrative complaint and authorized a lawsuit in federal court to block the proposed acquisition pending the Commission's administrative proceedings. A bipartisan group of nine attorneys general is joining the FTC's federal court complaint.

12:02 EST Infobird delays effective date of reverse split to March 4 - Infobird announced that the Company is amending the effective date for its reverse stock split to Monday March 4, 2024 to begin trading on a split-adjusted basis when the market opens, due to an unanticipated delay in obtaining necessary regulatory clearances. Previously, the Company had planned for its reverse split to become effective after the close of business on Monday, February 26, 2024, and had expected the ordinary shares to begin trading on a split-adjusted basis when the market opened the following day, Tuesday, February 27, 2024.

12:00 EST ProShares UltraShort Bloomberg Natural Gas falls -7.5% - ProShares UltraShort Bloomberg Natural Gas is down -7.5%, or -$11.06 to $136.08.

12:00 EST Gaotu Techedu rises 11.5% - Gaotu Techedu is up 11.5%, or 63c to $6.13.

12:00 EST Agiliti rises 29.2% - Agiliti is up 29.2%, or $2.23 to $9.87.

10:53 EST Perficient extends partnership with St. Louis Cardinals - Perficient announced a multi-year extension of its longstanding partnership with the St. Louis Cardinals. In addition to its in-stadium presence, Perficient will be featured on the Cardinals' flagship radio station, KMOX, as well as across the entire Cardinals Radio Network, which constitutes more than 140 stations across nine states.

10:13 EST Sandvik to acquire CAM reseller Cimquest, terms not disclosed - Sandvik has signed an agreement to acquire Cimquest, a U.S. based reseller of Computer Aided Manufacturing solutions. With the acquisition, Sandvik strengthens its position in the CAM market and further builds on its capabilities to serve customers and expand the customer base. Cimquest will be a part of business unit Mastercam and will be reported within business area Sandvik Manufacturing and Machining Solutions. Cimquest has since 1990 been a reseller of Mastercam, a global leading provider of CAD/CAM software solutions for manufacturing industries, owned by Sandvik. In addition to reselling Mastercam, Cimquest is a distributor of additive products, mainly 3D printers for both metal and polymers. Cimquest, founded in 1990, is headquartered in Branchburg, New Jersey, and has 55 employees. In 2023, the company had revenues of around $26M. The impact on Sandvik's EBITA margin will be limited. Impact on earnings per share will be positive. The parties have agreed not to disclose the purchase price.

10:05 EST McEwen Copper provides update on assay results at Los Azules - McEwen Copper announced assay results from the final unreleased drill holes of the last season. The results from this period not only validate previous drilling results but also confirm the continuity of mineralization and extend the mineralization. Selected Highlights: Hole AZ23205MET returned 257 m of 0.76% Cu within the Enriched zone. Hole AZ23228MET returned 446 m of 0.63% Cu in the Enriched zone, including 76 m of 0.92% Cu. Hole AZ23230MET returned 250 m of 0.68% Cu in the Enriched zone, including 192 m of 0.83% Cu. The objective of the 2022-2023 drilling campaign was to collect information needed as the project advances towards the completion of a Feasibility Study in Q1 2025. Work continues during this field season and includes resource drilling that will convert the initial 5-year pit resources to Measured and Indicated categories and will further upgrade resources from Inferred to Indicated. In addition to resource drilling, geotechnical, metallurgical, hydrogeological, exploration, and condemnation drilling are also being performed.

10:02 EST Rhode Island Energy selects Landis+Gyr to deploy smart grid technologu - Landis+Gyr and Rhode Island Energy have agreed to a contract to deploy and support advanced smart metering technology for 530,000 electric customers in the state. The utility will be installing Landis+Gyr's Revelo metering platform, featuring grid-edge sensing and edge computing capabilities to manage load and support grid troubleshooting. The Revelo meter operates on Landis+Gyr's RF Wi-SUN network, which also supports interaction with other smart energy and smart city devices.

10:00 EST Weave rises 12.1% - Weave is up 12.1%, or $1.29 to $11.93.

10:00 EST Agiliti rises 29.5% - Agiliti is up 29.5%, or $2.25 to $9.89.

10:00 EST ProShares UltraShort Bloomberg Natural Gas falls -6.7% - ProShares UltraShort Bloomberg Natural Gas is down -6.7%, or -$9.93 to $137.21.

09:52 EST Amazon to launch AWS infrastructure Region in Mexcio by 2025 - Amazon Web Services announced plans to launch an AWS infrastructure Region in Mexico by early 2025. The new AWS Mexico Region will give developers, startups, entrepreneurs, and enterprises, as well as government, education, and nonprofit organizations, greater choice for running their applications and serving end users from data centers located in Mexico, ensuring that customers who want to store their content in Mexico can do so. As part of its long-term commitment to Latin America, AWS is planning to invest more than $5B in Mexico over 15 years. The upcoming AWS Mexico Region is the latest in AWS's ongoing investments in Mexico to provide customers with advanced and secure cloud technologies. The new AWS Region will consist of three Availability Zones at launch, adding to AWS's existing 105 Availability Zones across 33 geographic regions globally.

09:52 EST Flyexclusive Inc trading resumes

09:48 EST Cisco, Orange Business sign MoU to accelerate GHG emissions reduction - Orange Business (ORAN) and Cisco (CSCO) have signed a Memorandum of Understanding for a joint action plan to help reduce their greenhouse gas emissions. The plan represents a first for both companies, deepening their partnership, and facilitating the sharing of data that will inform progress towards their net zero goals. They agree to create an emissions baseline regarding the GHG emissions of Orange Business solutions that integrate Cisco products, allowing both organisations to measure GHG emissions across their shared portfolio. The MoU includes a number of key focus areas that Cisco and Orange Business will work together on, including: 1. GHG Emissions Trajectory Cisco and Orange Business aim to build a GHG emissions trajectory for the Cisco products used by Orange Business. Both partners will use shared data to help estimate the GHG emissions related to Orange Business solutions integrating Cisco technology with the objective to reduce GHG emissions. 2. Carbon Impact of Products and Services Cisco aims to provide Orange Business with data on the estimated carbon footprint of Cisco products sold by Orange Business. This will allow Orange Business to integrate this data into their own emissions calculations in order to estimate the overall carbon footprint of Orange's solutions portfolio integrating Cisco products. Orange Business will then be able to provide their customers with an estimate of the total emissions of their supplied products and solutions. 3. Emphasis on Circular Economy Programs and Principles Cisco and Orange Business agree to focus on increasing the uptake of circular economy principles and practices by Orange Business and its customers. This will be done through two channels, first boosting the purchase of remanufactured units through the Cisco Refresh Program, then through the uptake of Cisco's Takeback and Reuse Program facilitated by Orange Business. 4. Eco-designed Products and Solutions of the Future Orange Business and Cisco will also endeavor to explore different ways to integrate eco-design principles into the design of products and services. For this purpose, Cisco will provide Orange Business with Lifecycle Analysis data for its products, when available. This will help Orange Business to reach its goal of a 100% rate of eco-designed solutions offered to its customers.

09:47 EST ProShares UltraShort Bloomberg Natural Gas falls -8.4% - ProShares UltraShort Bloomberg Natural Gas is down -8.4%, or -$12.40 to $134.74.

09:47 EST Domino's Pizza rises 8.6% - Domino's Pizza is up 8.6%, or $37.40 to $471.05.

09:47 EST Agiliti rises 29.3% - Agiliti is up 29.3%, or $2.24 to $9.88.

09:45 EST MicroCloud Hologram Inc trading resumes

09:41 EST Maravai LifeSciences trading resumes

09:36 EST Lakeshore Acquisition II Corp trading halted, volatility trading pause

09:26 EST Neptune Wellness places certain employees on mandatory unpaid leave of absence - Neptune Wellness Solutions has placed certain employees on a mandatory unpaid leave of absence effective February 23, 2024 in connection with a rapid cost cutting and restructuring effort, as a result of the Company's previously disclosed ongoing financial concerns. Among the employees placed on mandatory leave are Michael Cammarata, President and CEO, and John Wirt, Executive Vice President and Chief Legal Officer, both of whom are under employment contracts. Mr. Cammarata also concurrently resigned from the Company's board of directors and all other board positions at the Company's subsidiaries and affiliates effective immediately. Mr. Cammarata is challenging his unpaid leave under the terms of his employment agreement, and there is a risk of dispute under existing employment agreements as a result of the announced temporary leaves. The Company is currently working through a succession plan to determine who will assume the role of Interim CEO in Mr. Cammarata's absence. In the interim, the Company has appointed a special restructuring committee comprised of certain members of the Board to evaluate candidates for the role of Interim CEO and to lead the Company through this transitionary period. The last day of work for employees placed on mandatory leave was February 23, 2024. The initial period of mandatory leave is for thirty days, though any decisions to recall staff to active service, extend the period of leave, or relieve staff of responsibilities have not yet been made. The Company will continuously evaluate its financial condition as well as all available strategic alternatives in connection with its ongoing restructuring effort to determine when employees will be recalled to active service, though there can be no assurance at this stage that any of the employees will return to the Company at the end of the temporary period of mandatory leave, if at all.

09:20 EST Global Tech Industries communicates with brokerage firms over stock dividend - Global Tech Industries Group has communicated with eight major brokerage firms through a registered letter in order to ensure that the stock dividend issued on April 29, 2023 is appropriately deposited into shareholders' respective accounts. Furthermore, GTII wishes to inform shareholders that if they wish to deposit their shares in advance, they should complete a Stockholder's Representation Letter,, which outlines the procedures to deposit their shares in advance. In any event, GTII believes that all shareholders should have their shares deposited on or around April 29, 2024, which marks the one year date from the date of issuance of the stock dividend. Liberty Stock Transfer GTII's transfer agent is also sending out a general information letter to the brokers that offers further clarification and assistance in responding to the receipt of any Stockholder's Representation Letter, on the basis of a blanket legal opinion concerning the stock dividend held by Liberty. David Reichman, Chairman & CEO of GTII, stated, "We appreciate our shareholders' patience in awaiting the depositing of their 10% stock dividend. We will continue to support our shareholders and are doing everything we can to facilitate the process for them to obtain their dividend shares."

09:17 EST Bristol Myers completes acquisition of RayzeBio - Bristol Myers Squibb (BMY) announced that it has successfully completed its acquisition of RayzeBio (RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. Bristol Myers Squibb's previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1B, expired at one minute after 11:59 p.m., Eastern Time on February 22. Approximately 53,052,499 shares of RayzeBio common stock were validly tendered, and not validly withdrawn from the tender offer, representing approximately 86% of RayzeBio's issued and outstanding shares of common stock. In accordance with the terms of the tender offer, all shares that were validly tendered and not validly withdrawn have been accepted for payment and Bristol Myers Squibb expects to promptly pay for all such shares. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics, or 'RPTs,' one of the fastest-growing new modalities for treating patients with solid tumors. By strengthening and further diversifying our oncology pipeline beyond I-O, we will unlock exciting opportunities that support BMS's growth in the back half of the decade and beyond. RayzeBio is a pioneer in the application of this novel modality, and we look forward to working with their talented team to accelerate their preclinical and clinical programs for the benefit of patients around the world," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb.

09:15 EST Pressure BioSciences reports Uncle Bud's growth following acquisition - Pressure BioSciences announced early financial results from its January 19, 2024 acquisition of Uncle Bud's Health & Wellness. Key highlights from Uncle Bud's first month following its acquisition by PBIO include: Amazon Business Rapid Growth: Amazon sales have surged, increasing 60% over the previous month. This acceleration leverages underlying growth in consumer demand for Uncle Bud's trusted natural wellness products. Direct-to-Consumer Sales Increase: DTC sales experienced a 16% increase from the previous month, reflecting the solidifying base of loyal customers and a growing interest in the brand's unique offerings. Expansion of DTC Customer Base: New DTC customers have grown by 13% compared to the previous month, reflecting the brand's expanding appeal and its successful outreach efforts. Unprecedented DTC Subscription Growth: New DTC subscriptions have surged by a robust 138% since the previous month, showcasing consumers' growing trust and preference for UB's products. Website Traffic Increase: Unique visitors to UB's website have increased by 142%, signaling a significant rise in brand awareness and interest in the brand's holistic wellness solutions. Celebrity Endorsements on the Horizon: UB is in discussions with several high-profile celebrities to join UB, with compelling personal endorsements to further elevate the brand's visibility and appeal. Influencer Campaign Launch: UB is set to launch an extensive influencer campaign, partnering with one of the largest influencer platforms to engage both micro and macro influencers. This initiative is expected to broaden the brand's reach and deepen its connection with consumers. Premium Collection Introduction: UB recently announced the introduction of a new Premium Collection of products, all of which will be processed with PBIO's revolutionary, patented UltraShear nanoemulsification platform, resulting in measurably increased speed of action, dosing payload delivery, bioavailability, and stability.

09:13 EST Pearson announces plans to expand generative AI study tools - Pearson announced plans to further expand its beta AI study tools into additional Pearson+ eTextbooks. "We've had a great response to our AI offering from students and instructors, and we're excited for millions more to experience these features this year. As we expand our AI study tools, we are learning more about what students want and are acting on their feedback. When we combine learning science and trusted content with AI technology, our products are even more effective in helping students learn and instructors teach," said Tony Prentice, Pearson's Chief Product Officer.

09:12 EST Collins Elbit delivers 3,000th F-35 Gen III Helmet display system - Collins Elbit Vision Systems - a joint venture between Collins Aerospace, and Elbit Systems of America - announced that it has delivered the 3,000th F-35 Gen III Helmet Mounted Display Systems to the Joint Strike Fighter. Collins Aerospace is an RTX business.

09:10 EST Rakuten Symphony, Kyivstar sign LOI to deploy Open RAN in Ukraine - VEON announces that its wholly-owned subsidiary Kyivstar and Rakuten Symphony have signed of a Letter of Intent that confirms Kyivstar's interest in procuring and deploying Rakuten Symphony's Open Radio Access Network technology in its network. The LoI confirms Kyivstar's intent to use Rakuten's Open RAN and 5G technologies to help rebuild Ukraine's digital infrastructure, reinforcing both companies' commitment to supporting Ukraine's recovery and reconstruction. The companies intend to take the first steps in the implementation of their cooperation within 2024. Kyivstar and Rakuten Symphony are currently collaborating to define the scope of their initiative, which will involve both 4G and 5G Open RAN technology.

09:08 EST Gevo appoints Damien Perriman as chief business development officer - Gevo announced that Damien Perriman has been hired as Chief Business Development Officer to lead the effort to bring in new business in a wider variety of industry sectors and expand the brand footprint for the company. His most recent position was as Senior Vice President, Specialty Products for Genomatica, a company focused on accelerating the transition to sustainable materials by developing and producing intermediate and basic chemicals from plant-based sources.

09:08 EST Quanterix announces collaborations with health systems - Quanterix announced its first collaborations with health systems in pursuit of their shared goal to improve and simplify Alzheimer's disease, or AD, diagnosis. These relationships further the company's goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix's leading blood biomarker assays. Collectively AdventHealth, Mass General Brigham, Mayo Clinic, South Carolina Alzheimer's Disease Research Center at the Medical University of South Carolina, and UPMC represent 140+ hospitals across 18 states, caring for approximately 21M patients in their hospital networks. This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.

09:06 EST Modine Manufacturing to buy Scott Springfield Manufacturing for $191M - As previously announced, Modine Manufacturing has entered into a definitive agreement to acquire Scott Springfield Manufacturing, a leading manufacturer of air handling units, or AHU. In a regulatory filing, the company disclosed that the aggregate purchase price to be paid by the company to the seller parent will be C$257.0M, or approximately $191M, on a cash-free, debt-free basis. Modine expects to fund the purchase price with a combination of cash on hand and from its existing credit facility; as such, the closing of the transaction is not conditioned on the receipt of financing by the purchaser or Modine. Reference Link

09:05 EST TiVo signs four operators to TiVo Broadband - TiVo Platform Technologies the company that brings entertainment together and a wholly owned subsidiary of entertainment technology company Xperi announced that TiVo Broadband, a new solution specifically tailored for operators' broadband-only customers, has signed four operators. This rapid success and footprint expansion comes quickly on the heels of the initial launch of TiVo Broadband in January 2024 at CES. TiVo is dedicated to delivering a better entertainment experience for its customers and end users in a way that feels more intuitive and personal. TiVo Broadband leverages cutting-edge technology that powers the TiVo IPTV Platforms, which allows operators to enhance the streaming video experience for their broadband-only customers across a range of devices. In addition, TiVo Broadband delivers premium subscription video-on-demand SVOD , TiVo's Free Ad-Supported Television FAST content network TiVo+, and customer-specific linear channels to an operator's broadband-only customer base. "Broadband providers have unique opportunities to harness the popularity of streaming to expand into new branded entertainment services," said Greg Ireland, IDC's Future Consumer research director. "A robust entertainment experience platform running on a connected device offers broadband providers a way to deliver a rich variety of streaming services to customers."

09:04 EST ARS Pharmaceuticals reports neffy meets primary endpoints in Phase 2 study - ARS Pharmaceuticals announced efficacy results in its phase 2 inpatient chronic spontaneous urticaria study with neffy, an investigational new drug. The trial met its primary endpoints with both 1 mg and 2 mg neffy demonstrating statistically significant and clinically meaningful changes from baseline in itch, hives, urticaria and erythema scores as early as 5 minutes after dosing. Urticaria is a skin disorder that causes itchy hives and/or angioedema; 50% of chronic urticaria cases1 are non-responsive to first-line antihistamine therapy. These data for neffy are being presented in an oral presentation today, February 26, at 1:10 pm ET at the 2024 American Academy of Allergy, Asthma and Immunology in Washington, D.C. in Room 207B of the Convention Center. The EPI-U01 study was a randomized, placebo-controlled, cross-over study evaluating the safety and efficacy of epinephrine nasal spray in patients with chronic spontaneous urticaria treated with chronic medications who were still experiencing flares. This oral presentation includes data analysis from 18 adult patients as of the cut-off date who enrolled in this study and returned to the clinical site while experiencing a flare, where they were randomized to receive either a single treatment of 1 mg or 2 mg neffy or placebo in a crossover design. All subjects had flares with pruritus and hives scores greater than or equal to 2 on a 3 point severity scale, despite all patients having been treated with antihistamines or Xolair. There was no meaningful difference in efficacy on patient-reported itch severity score, patient-reported hives severity score, investigator-related extent of urticaria, or investigator-related erythema score between 1 mg and 2 mg neffy doses, indicating that the 1 mg dose may be sufficient to activate the beta-2 adrenergic receptors responsible for stopping the mast cell degranulation and allergic mediator release that leads to an urticaria flare. neffy was well-tolerated, with adverse events reported in 8 subjects, which were all mild or moderate in severity. The most common adverse event reported was nasal discomfort in 5 subjects. There were no serious adverse events.

08:57 EST R1 RCM jumps 30% to $14.41 after New Mountain Capital buyout interest

08:54 EST Rail Vision gets approval for Main Line system for operation across EU - Rail Vision announced an advancement through the approval and compliance of its Main Line system for operation across the European Union. This achievement, which was recently announced, sets a new standard in railway safety and opens the door for unprecedented growth and adoption of Rail Vision's technology in the expansive EU market. The Main Line system, Rail Vision's flagship innovation, has been officially approved and is now poised to redefine railway safety and operational efficiency throughout Europe. This state-of-the-art system offers unparalleled capabilities in detecting and identifying objects on and near tracks in real time, significantly reducing the risk of accidents and enhancing the overall safety of railway operations. With this approval, Rail Vision is set to accelerate the adoption of its Main Line system, showcasing the potential to dramatically improve railway safety standards across the EU. This milestone is a testament to Rail Vision's technological prowess and also aligns with the EU's commitment to enhancing transport safety and efficiency.

08:51 EST CLS Holdings announces repayment of debenture obligations - CLS Holdings USA announced its continuing efforts to aggressively retire debt at a discount to the Company, on February 23, 2024 CLSH retired a total of $1,526,250 in Principal and Interest Repayment Obligations owed by the Company. This debt reduction was achieved through the repurchase of $1,200,000 in Principal Amount of 15% Debentures, with interest forgiven in the amount of $326,250. As part of the Debt Repurchase, CLSH also acquired 13,274,780 of its issued and outstanding shares previously held by the debenture holder, thereby strengthening Shareholder Value by reducing the overall number of issued and outstanding shares. The Shares Repurchased had a value of 0.0450 per share or $597,365.10. As a result of the repurchase of shares, the total outstanding issued shares of the Company was reduced from 137,675,276 to 124,400,496. The retirement of the debt and the repurchase of shares was financed through a series of four loans totaling $1,350,000, with 12% interest, payable monthly, over the course of 24 months. These new loans represent a material reduction in the interest rate and a significant extension of the duration for payment over the notes that have been repurchased using those funds.

08:49 EST Faraday Copper announces metallurgical results at Copper Creek Project - Faraday Copper announced the results of its metallurgical program at its Copper Creek project in Arizona, USA. The metallurgical program was designed to evaluate grind size optimization, gold recoveries, and test additional samples from the near-surface mineralization to further enhance project economics compared to the Preliminary Economic Assessment 1. Key highlights include: Achieved copper rougher 2 recoveries of 95% in the sulphide composite by applying a substantially larger grind size 3. The increased grind size confirms the following benefits: Opportunity to increase copper rougher recoveries to over 97% by utilizing Coarse Particle Flotation scavenging. CPF supports a potential increase to mill throughput without increasing the tailings pressure filtration requirement; Significant reduction in ball mill grinding energy compared to the PEA; and Maintained copper concentrate quality with a consistently high average concentrate grade of 30.5% copper. Confirmed gold recoveries in copper concentrate of over 75% supporting the potential for payable gold in the copper concentrate, which was not considered in previous studies. Significantly improved near-surface oxide recovery through column leach tests, which returned copper recoveries of 84% to 92% in 43 days with net acid consumption less than12 kg/t, compared to 75% in 60 days with net acid consumption of 20 kg/t utilized in the PEA. Based on the outcomes of the metallurgical program and ongoing exploration results, the Company is targeting the following steps to continue to enhance the value of the project: Exploration Drilling: Phase III drilling continues and is focused on reconnaissance drilling on new targets, expanding the Mineral Resource and better delineating high-grade mineralized zones. Gold Assay Program: The Company continues to advance the gold assay program, currently focused on the Keel underground zone. Assay results from this program, paired with existing gold data, could support the inclusion of gold in future resource updates and project economics. Metallurgical Assessments: Test work will be conducted as new resource targets are delineated. In addition, continued assessments will include further CPF flowsheet evaluation and a material type characterization program. Technical Report Update: To incorporate updated geological, geotechnical, economic and metallurgical datasets.

08:45 EST MicroStrategy acquired about 3,000 bitcoins for $155.4M over February 15-25 - In a regulatory filing, MicroStrategy announced that, during the period between February 15 and February 25, MicroStrategy, together with its subsidiaries, acquired approximately 3,000 bitcoins for approximately $155.4M in cash, at an average price of approximately $51,813 per bitcoin, inclusive of fees and expenses. The bitcoin purchases were made using proceeds from the issuance and sale of shares under the company's existing sales agreement and excess cash. As of February 25, MicroStrategy, together with its subsidiaries, held an aggregate of approximately 193,000 bitcoins, which were acquired at an aggregate purchase price of approximately $6.09B and an average purchase price of approximately $31,544 per bitcoin, inclusive of fees and expenses. Reference Link

08:40 EST Ondas establishes subsidiary Ondas Autonomous Holdings - Ondas Holdings has established Ondas Autonomous Holdings as a new, wholly owned subsidiary. The newly created OAH is an intermediate holding company which now wholly-owns Ondas' subsidiaries American Robotics and Airobotics, which are together operated as the Ondas Autonomous Systems business unit. The creation of OAH is intended to provide additional organizational flexibility to support the management and financing of the OAS business unit and its growth plan. OAS has demonstrated strong early revenue momentum which is expected to accelerate. On a preliminary, unaudited basis OAS generated $9.0 million in revenue for the year ended December 31, 2023.

08:38 EST Tenaya Therapeutics announces publication of preclinical HDAC6 inhibitor data - Tenaya Therapeutics announced the publication of preclinical research related to Tenaya's small molecule inhibitors of histone deacetylase 6, including TN-301, in the February 26, 2024, issue of Nature Communications. The article, titled "Targeting HDAC6 to Treat Heart Failure with Preserved Ejection Fraction in Mice," details the potential of inhibiting HDAC6 for the treatment of Heart failure with preserved ejection fraction, a form of heart failure that effects more than three million people in the U.S. alone. The extensive body of preclinical research described in Nature Communications showed that inhibition of HDAC6: Successfully addressed many of the biologic hallmarks of HFpEF, with direct effects on the heart such as diastolic relaxation and systemic benefits including normalization of metabolic and inflammatory factors, in a preclinical murine model that replicates the HFpEF disease state. Achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, a sodium-glucose cotransporter-2 inhibitor approved by the U.S. Food and Drug Administration as a treatment for HFpEF. Showed additive benefits when combined with empagliflozin compared to either agent alone, indicating the potential for the use of a small molecule HDAC6 inhibitor alone or as a combination therapy for the treatment of HFpEF. Last year, Tenaya completed a Phase 1 clinical trial in which TN-301 achieved encouraging safety, target engagement and pharmacokinetic results across a wide range of doses tested in healthy participants. Tenaya's highly selective small molecule inhibitors of the enzyme HDAC6 were discovered using the company's modality-agnostic target discovery and validation capabilities. Unlike other members of the HDAC family, HDAC6 is localized to the cell cytoplasm where it coordinates cellular processes through interactions with multiple substrates, including tubulin, and tubulin acetylation was identified as a reliable plasma biomarker of HDAC6 target engagement. Having previously reported on the cardioprotective qualities of HDAC6 inhibition in a model of genetic cardiomyopathy, researchers set out to assess the potential of HDAC6 inhibition in HFpEF using multiple models of HFpEF, including a proprietary high fat diet and moderate transverse aortic constriction murine model that replicated the metabolic and mechanical stress seen in patients with HFpEF. For preclinical studies, Tenaya researchers used TYA-018, an HDAC6 inhibitor structurally and functionally similar to the company's clinical candidate, TN-301. Key Findings Treatment with TYA-018 as a single agent resulted in direct effects on the heart, and systemic benefits. TYA-018 showed comparable benefit to empagliflozin in the murine HFpEF model. Gene expression analysis provided insights on TYA-018's distinct mechanism of action. HDAC6 inhibition was shown to restore hypertrophy, fibrosis and mitochondrial energy production. TYA-018 demonstrated greater impact on markers of oxidative stress, inflammation and metabolism as compared to SGLT2 inhibition. The combination of TYA-018 and empagliflozin resulted in additive benefits, exceeding the efficacy observed with either agent alone with measurements of cardiac function nearing that of healthy controls. The selective effects of HDAC6 inhibition were reaffirmed through genetic deletion studies, in which treatment of Hdac6 knockout mice did not display any of the beneficial effects that wild-type HFpEF mice did following treatment.

08:36 EST ProStar, Topcon announces technology integration with PointMan - ProStar Holdings announced a technology integration with Topcon Corp. The integration combines ProStar's utility mapping software, PointMan, and Topcon's fixed and portable GNSS antennas. The technology integration provides Topcon users with a seamless and easy to use utility data collection solution to capture, record, and display the precise location of critical underground infrastructure anywhere in the world. The technology integration of PointMan with Topcon GNSS receivers means that PointMan now supports Topcon Hiper VR highly versatile GNSS receivers for mobile devices running the Google Android operating system. The seamless integration empowers Topcon users with PointMan's unparalleled precision in subsurface utility mapping.

08:35 EST KKR to acquire EUC division from Broadcom in $4B transaction - KKR (KKR) announced the signing of a definitive agreement with Broadcom (AVGO) to acquire its end-user computing division, or EUC Division, in a transaction valued at approximately $4B. Upon closing of the transaction, the EUC Division will become a standalone company, with greater access to growth capital and a dedicated strategic focus on empowering customers and partners worldwide with innovative digital workspace solutions. KKR is making its investment primarily through its North America Fund XIII. The transaction is expected to close in 2024, subject to customary closing conditions, including regulatory approvals.

08:35 EST NRx Pharmaceuticals launches HOPE Therapeutics at BIO Conference - NRx Pharmaceuticals announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024, at the Marriott Marquis in New York City. "Subsequent to our announcement last week, we are in the process of completing a Memorandum of Understanding that may enable us to begin sales of IV ketamine to qualified clinics in partnership with a holder of a nationwide pharmacy license. Additionally, we will be updating investors with regard to our plans to add a digital therapeutic component to our ketamine offering that has potential to extend the clinical benefit to patients." said Dr. Javitt. "We thank our investors for their support and look forward to updating the public on our progress towards building a lifesaving therapy."

08:33 EST Sapiens, DataCrest forge partnership to elevate underwriting precision - Sapiens International Corporation and DataCrestannounced the formation of a strategic partnership to revolutionize the application process and drive premium growth for P&C insurers. "The collaboration between Sapiens and DataCrest promises a multitude of benefits for P&C insurers, including an advanced front-end solution designed to streamline applications/submission intake and boost efficiencies to improve underwriting decision making," said DataCrest's CEO Tom Young. "With DataCrest's expertise and Sapiens' cutting-edge solutions, this partnership aims to redefine industry standards by increasing the ease of doing business, driving premium growth, and lowering loss ratios."

08:32 EST Lixte Biotechnology enters patent license agreement with NINDS, NCI - LIXTE Biotechnology Holdings announced the signing of an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and National Cancer Institute, each a component of the National Institute of Health. Under the terms of the license agreement, LIXTE has licensed exclusively NIH's intellectual property rights claimed for a Cooperative Research and Development Agreement subject invention co-developed with Lixte, and the licensed field of use, which focuses on promoting anti-cancer activity alone, or in combination with standard anti-cancer drugs. The scope of this clinical research extends to checkpoint inhibitors, immunotherapy, and radiation for the treatment of cancer.

08:29 EST Avant Brands restructures loan agreements to extend term, decrease payments - Avant Brands has entered into amendments with respect to certain outstanding debts of the Company. Avant has entered into a promissory note extension agreement, with MENA Investment Network pursuant to which certain amendments were made to the terms of the original promissory note dated July 31, 2023. The Extension Agreement benefits the Company as the Note's $720,000 balance, originally due on the Note's due date, will now be paid through monthly installments until the amended maturity date of July 12, 2024. The Note bears interest at a rate of 12% percent per annum. Subject to final approval of the TSX, as consideration for entering into the Extension Agreement, Avant: issued 672,897 common shares of the Company to MENA; and subject to certain conditions will additionally issue such number of common shares of the Company on July 12, 2024, equal to $50,000 divided by the five-day volume weighted average price of the common shares of the Company on the Toronto Stock Exchang. Avant has entered into a partial equity conversion agreement with F-20 Developments Corp. reducing Avant's quarterly payments to F-20 by more than $1,250,0000. Additionally, Avant and F-20 have executed an amended and restated convertible debenture, replacing in its entirety the debenture dated February 1, 2023. Subject to final approval of the TSX, and in accordance with the Equity Conversion Agreement, Avant has made a voluntary prepayment to F-20 against the principal balance of $4,750,000 in the amount of $1,400,000 through the issuance of 16,355,140 common shares of the Company. Additionally, Avant issued 1,375,000 common share purchase warrants to acquire common shares of the Company at an exercise price of $0.25 on or before February 23, 2026, subject to acceleration by the Company in the event that the 20-day VWAP of the Common Shares on the TSX exceeds $0.85. Terms of the A&R Debenture include: a maturity date extension to October 29, 2025; monthly amortized payments of approximately $150,000; and the amended note shall bear an interest rate of 15% per annum.

08:26 EST Fury Gold Mines consolidates interests at Eleonore South gold project - Fury Gold Mines (FURY) announce that Fury and certain affiliates of Newmont Corporation (NEM) have entered into an agreement whereby Fury will purchase Newmont's 49.978% interest in Eleonore South for C$3M. As part of the consolidation of Eleonore South, Fury has also agreed to purchase Newmont's 30,392,372 shares of Sirios Resources for C$1.3M. The Sirios shares will be acquired for investment purposes and Fury will evaluate its investment in Sirios on an ongoing basis with respect to any possible additional purchases or dispositions. Completion of the purchase is subject to certain conditions precedent and is expected to close in late February or early March 2024. "We value the strong relationship with Newmont and are confident that this transaction is a positive outcome for both companies," commented Tim Clark, CEO of Fury. "Our team has historically ranked the ESJV as one of our more prolific targets for discovery. As such, we are excited to now have 100% ownership as we expect this to provide a clearer pathway for more exploration and potential upside in returns for our investors from this project consolidation and investment in Sirios."

08:24 EST Enphase Energy starts shipping home energy systems in Italy - Enphase Energy has started production shipments of its most powerful home battery to-date, the IQ Battery 5P, for customers in Italy. The IQ Battery 5P is a modular design with 5 kWh capacity and can be paired with the new IQ8 Microinverters to provide homeowners reliable electricity to use whenever they need it.

08:22 EST Hoth Therapeutics engages Altasciences to perform key study for HT-KIT - Hoth Therapeutics announced that it has completed bioanalytical method development under its prior agreement with Altasciences and plans to further engage Altasciences to perform a key study of mouse blood and plasma analysis from samples collected in Hoth's sponsored scientific research conducted at NC State University. The blood and plasma samples collected are part of a dose response study in a humanized mouse model. The upcoming study will use the newly validated bioanalytical method developed at Altasciences to test the amount of HT-KIT from the dose response study and help determine how long HT-KIT remains in the blood stream post dosing. "We continue to make strides in moving HT-KIT from the lab to patients and this further analysis will help us with that process as a final step in the preclinical development that allows us to finalizing the protocols in our upcoming IND-enabling," stated Robb Knie, Chief Executive Officer. "We are pleased to further engage Altasciences on these studies given its great reputation for full-service solutions including preclinical safety testing, clinical pharmacology and bioanalysis."

08:19 EST Orchestra BioMed presents new data on long-term effect of AVIM therapy - Orchestra BioMed Holdings (OBIO) announced the presentation of new data demonstrating the long-term effect of atrioventricular interval modulation therapy on generating clinically-meaningful reductions in 24-hour ambulatory systolic blood pressure in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. The data were presented by Avi Fischer, M.D., Senior Vice President of Medical Affairs and Innovation of Orchestra BioMed in a scientific session at the Innovation in Cardiovascular Interventions 2024 Meeting. Reduction in aSBP measured at 6 months from randomization and therapy activation was the primary endpoint of the MODERATO II study, a European multi-center, double-blind, randomized pilot study involving 47 subjects. Patients randomized to AVIM therapy and antihypertension medication in that study experienced an 11.1 mmHg reduction in mean aSBP at 6 months follow-up, resulting in a statistically significant difference of 8.1 mmHg compared to control patients who were managed only with antihypertensive medications. Long-term blood pressure results are from a follow-up study of 16 patients originally enrolled in the MODERATO II study. This group included eight patients from the MODERATO II AVIM treatment arm and eight control arm patients that crossed over to AVIM therapy at the end of the 6-month double-blind phase. Each patient's aSBP was measured an average of 3.6 years following original initiation of AVIM therapy. As a group and based on individual paired data, these patients continued to experience a statistically significant, clinically meaningful mean aSBP reduction of 8.9 mmHg, identical to the 8.9 mmHg mean reduction in aSBP seen in this same group of patients at the 6-month primary aSBP measurement endpoint of the original study. AVIM therapy is an investigational patented bioelectronic therapy, administered using a standard dual-chamber pacemaker, designed to immediately, substantially and persistently reduce blood pressure. Orchestra BioMed and Medtronic plc (MDT) formed a strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker patients in July 2022. If AVIM therapy is approved by the U.S. Food and Drug Administration, Medtronic will have exclusive global rights to commercialize AVIM-enabled pacing systems for this target population, and Orchestra BioMed will share in the revenues generated from Medtronic sales of the AVIM-enabled pacing systems. Orchestra BioMed is actively enrolling patients in the BACKBEAT pivotal study, a global, multi-center, prospective, randomized, double-blind study investigating the efficacy and safety of AVIM therapy in patients who have recently undergone implantation of a Medtronic dual-chamber cardiac pacemaker and have uncontrolled hypertension despite the use of antihypertensive medications. The study's primary efficacy endpoint will determine at three months post-randomization whether AVIM-treated patients experience a statistically significant reduction in aSBP as compared to control patients.

08:15 EST Arrow Electronics and Infineon team to accelerate automotive electrification - Arrow Electronics (ARW) and its engineering services company, eInfochips, are working with Infineon Technologies (IFNNY) to help eInfochips' customers accelerate the development of electric vehicle EV chargers. Development of EV chargers, especially DC "fast chargers," is becoming increasingly challenging to equipment manufacturers due to several factors, such as lack of prior experience, stringent functional safety and reliability requirements, and a fledgling support network. The collaboration between Arrow and Infineon aims to help innovators navigate these challenges while accelerating time-to-market. As part of the collaboration, Arrow's High Power Center of Excellence has developed a 30kW DC fast charger reference platform. This includes Infineon's 1200V CoolSiC Easy power modules and also hardware design, embedded firmware, bi-directional charging support and energy metering functionality. "Combining Arrow's strength in components, engineering and design services with Infineon's innovative products will help customers accelerate their design and speed to market in e-mobility applications," said Murdoch Fitzgerald, vice president, global engineering and design services at Arrow. "

08:13 EST Mizuho Americas names Rose Zhang as brand ambassador - Mizuho Americas, part of one of the largest financial institutions in the world and title sponsor of the Mizuho Americas Open, today announced Rose Zhang, the 2023 Mizuho Americas Open champion who immediately prior spent a record 141 weeks as the top-ranked amateur in the world, as an official brand ambassador. She joins Michelle Wie West and Ayaka Furue representing "Team Mizuho." Upon winning the Mizuho Americas Open, Zhang became the first player since 1951 to win in her professional debut on the LPGA Tour. Since turning pro, Zhang has recorded seven top-10 finishes and represented the United States during the 2023 Solheim Cup.

08:11 EST Agiliti to be taken private in $10.00 per share merger agreement - Agiliti announced that it has entered into a definitive merger agreement pursuant to which an affiliate of private equity firm Thomas H. Lee Partners, the company's majority shareholder, will acquire all outstanding shares of Agiliti common stock not currently owned by THL and its affiliates and certain management shareholders for $10.00 per share in cash, implying an enterprise value of approximately $2.5B. The purchase price represents premia of approximately 39% and 43% over Agiliti's 30-day and 90-day volume weighted average price per share, respectively, as of February 23, 2024, the last trading day prior to public disclosure of the transaction. A special committee of the Agiliti board of directors, comprised solely of non-management directors not affiliated or associated with THL and advised by its own independent legal and financial advisors, determined that the proposed transaction is in the best interest of Agiliti and its shareholders. Acting upon the unanimous recommendation of the Special Committee, the Agiliti board of directors approved the transaction. The transaction is expected to close in the first half of 2024, subject to customary closing conditions. The transaction has been approved by THL Agiliti LLC in its capacity as the majority shareholder of Agiliti and no other shareholder approval is required. Upon completion of the transaction, Agiliti will become a private company and will no longer be publicly listed or traded on the New York Stock Exchange.

08:11 EST Standard BioTools, NGD partner for automation of pathogen sequencing - Standard BioTools and Next Gen Diagnostics announce the execution of a long-term agreement aimed at revolutionizing the automation of sample preparation for pathogen whole genome sequencing. Under the exclusive agreement, Standard BioTools will manufacture the NGD-100, a version of its microfluidics-based Biomark X9 System customized for NGD and optimized for automated pathogen WGS library preparation.

08:09 EST Matinas BioPharma provides update from Compassionate/EUA Program with MAT2203 - Matinas BioPharma provided an update from its ongoing Compassionate/Expanded Use Access Program with MAT2203, the Company's proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B. To date, 19 patients have been enrolled in the Program at prestigious healthcare institutions, including the University of Michigan, Johns Hopkins, Nationwide Children's Hospital, City of Hope, Vanderbilt University Medical Center, the National Institutes of Health, Children's Hospital of Philadelphia, Memorial Sloan Kettering Cancer Center, and the University of California, San Diego School of Medicine. The majority of enrolled patients are post-transplant or are undergoing treatment for underlying malignancies. The infections being treated with MAT2203 include a variety of micro-organisms occurring at multiple sites of infection, including brain, bladder/colon, bone, lung, sinus, and skin. Most patients were receiving AmBisome prior to enrollment but developed treatment-limiting nephrotoxicity and most also required treatment for either azole-resistant organisms or had clinically failed azole therapy and had no other treatment options. Of the 19 patients enrolled in the Program, 15 have available follow-up and 4 recently initiated or will soon commence treatment with MAT2203. 12 of the 15 patients had either complete clinical resolution or objective improvement in clinical markers of infection. Of the 5 patients who completed their full individually specified course of treatment all have had complete clinical resolution with no relapses or recurrence of their infection. 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned. 5 of the 15 patients were unable to complete their individually specified course of treatment, although 2 saw significant clinical improvement of their fungal infection and are included in the 12 overall successful cases. 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease. 1 patient discontinued therapy after two days due to underlying GI issues. 1 patient passed away due to progression of their underlying disease approximately 8 weeks into therapy. 1 patient discontinued MAT2203 treatment following 10 weeks of therapy due to underlying GI issues but with improvement in their fungal infection. Importantly, all patients who experienced renal toxicity following treatment with AmBisome saw their renal function return to baseline after transitioning to MAT2203 therapy and suffered no further renal side effects over the course of extended treatment with MAT2203.

08:08 EST Green Dot appoints Michael Meston as chief human resources officer - Green Dot announced the appointment of Michael Meston as chief human resources officer. Meston will play a key role in the company's evolution as a performance-driven platform company that now operates primarily in a remote "work from anywhere" model. He will report directly to CEO George Gresham.

08:07 EST Stagwell's Anomaly Alliance enters agreement with WNP - Stagwell has reached an agreement to acquire WHAT'S NEXT PARTNERS, WNP, a French digital brand and marketing consultancy specializing in data-powered strategies, integrated communications, and creative content. WNP will become the first co-branded member of the Anomaly Alliance in a partnership model designed to expand Anomaly's global footprint beyond its existing offices in New York, Los Angeles, Toronto, London, Berlin, and Shanghai. "2023's exceptional new business pipeline made it clear Stagwell's proposition resonates with clients," added Mark Penn, Chairman and CEO, Stagwell. "We're all-in on expanding our unique tech-forward approach to transforming marketing in France and Europe more broadly. In 2024, we're excited to welcome tested leaders like WNP and Guy and to build a best-in-class European team to support our clients and our talent."

08:06 EST Krystal Biotech sees 2024 non-GAAP R&D, SG&A expense $150M-$175M

08:05 EST IceCure Medical announces new preliminary data on ProSense - IceCure Medical announced new data from a preliminary, independent breast cancer study conducted by Principal Investigator and ProSense user, Dr. Federica. di Naro, of Azienda Ospedaliero-Universitaria Careggi, Diagnostic Senology Unit in Florence, Italy. IceCure previously announced interim results from this study on October 5, 2023. ProSense is approved in Italy for numerous indications, including breast cancer. In the single-site study conducted between January 2022 and January 2024, ultrasound-guided cryoablation using ProSense was performed on 39 women aged 60-92, who had biopsy-proven malignant lesions, and were deemed inoperable due to advanced age and comorbidities, or who refused surgery. Patients were monitored at 1, 3, 6 and 12 months post-procedure, at which time the tumor size reduction rate was evaluated by ultrasound. The median breast cancer tumor size reduction rates reported in the study were as follows:1 month: 27.8%; 3 months: 60.9%; 6 months: 100.0%; 12 months: 100.0%

08:03 EST Cogent Biosciences expects cash to fund requirements into 2027 - As of December 31, 2023, Cogent had cash, cash equivalents and marketable securities of $273.2 million. Cogent believes this year-end balance, together with the gross proceeds from the $225.0 million oversubscribed private placement, which closed February 16, 2024, will be sufficient to fund its operating expenses and capital expenditure requirements into 2027, including through clinical readouts from the ongoing SUMMIT, PEAK and APEX registration-directed trials.

07:59 EST Microchip launches new family of dsPIC-DSC-based integrated motor drivers - To implement efficient, real-time embedded motor control systems in space-constrained applications, Microchip Technology has launched a new family of dsPIC Digital Signal Controller-based integrated motor drivers. These devices incorporate a dsPIC33 digital signal controller, a three-phase MOSFET gate driver and optional LIN or CAN FD transceiver into one package. A significant benefit of this integration is reduction in component count of the motor control system design, smaller printed circuit board dimensions and reduced complexity. The devices are supported by development boards, reference designs, application notes and Microchip's field oriented control (FOC) software development suite, motorBench Development Suite V2.45.

07:57 EST NioCorp delivers advance notice under Standby Equity Purchase Agreement - NioCorp Developments has delivered a written notice pursuant to the previously announced Standby Equity Purchase Agreement, dated January 26, 2023, requesting the purchase of 75,000 shares of the Company's common shares, without par value. The Company has elected an Option 2 Pricing Period. Subject to the satisfaction of certain conditions contained in the Standby Equity Purchase Agreement, the Advance Shares will be issued at a purchase price equal to 97% of the daily volume-weighted average price of the Common Shares on The Nasdaq Stock Market as reported on Bloomberg Financial Markets during a pricing period of three consecutive trading days commencing on the date hereof. The Company expects the issuance and sale of the Advance Shares will close on or about February 29, 2024.

07:53 EST iBio to sell preclinical PD-1 agonist antibody program to Otsuka - iBio (IBIO) entered into an asset purchase agreement with Otsuka Pharmaceutical Co., (OTSKY), pursuant to which Otsuka acquired iBio's assets related to its early-stage programmed cell death protein 1 agonist program. The transaction closed on February 25, 2024. Under the terms of the Agreement, iBio will receive an upfront payment of $1.0 million in cash at closing. iBio will also be eligible to receive additional contingent cash payments totaling up to $52.5 million upon the achievement of certain pre-specified clinical development and commercial milestones.

07:50 EST NFI Group's Alexander Dennis says Enviro400EV bus completes Zemo testing - NFI Group's Alexander Dennis announced that its next-generation Enviro400EV electric double decker has completed the Zemo Partnership's zero-emission bus testing and certification program. The work, which was undertaken at UTAC's approved test facility at Millbrook Proving Ground, confirms an average energy consumption of just 0.67kWh/km across the UK Bus Cycle. This makes the next-generation Enviro400EV the most efficient battery-electric double decker tested to Zemo Partnership standards to date, delivering a 10% efficiency advantage over competitors' vehicles of comparable battery size.

07:48 EST Markel appoints Mike Heaton as Executive VP, COO - Markel Group announced that Mike Heaton will become Executive Vice President, VP, and Chief Operating Officer, COO, effective today. In this expanded role, he will oversee the day-to-day operations of the holding company and continue developing the system that supports Markel Group's family of companies. Heaton has a substantial track record supporting the businesses in Markel Group. Most recently, he was Executive Vice President, where he led the transformation from Markel Corporation to Markel Group.

07:47 EST AirBoss of America provides reportable segments update - Beginning with the fourth quarter and year ended December 31, 2023, AirBoss will report results under two reportable segments: AirBoss Rubber Solutions, and AirBoss Manufactured Products. The new Rubber Solutions segment will consist of the former rubber solutions segment and the rubber compounding operations at Acton Vale, Quebec previously included in the AirBoss Defense Group segment. The new Manufactured Products segment will consist of AirBoss Engineered Products, formerly a standalone segment, and AirBoss Defense Group, formerly a standalone segment. AirBoss' senior leadership team undertook an in-depth strategic review of the entire organization, which yielded a blueprint for a strategic transition related to the future growth of the Company. AirBoss' strategic transition is reflected in these new reportable segments. This transition will consolidate all rubber compounding operations into one segment, emphasizing this segment's ability to act as the core driver for sustainable growth and productivity. ARS will focus on innovation in custom rubber compounding, while aiming to expand market share through organic and inorganic means. The segment will strive to achieve enhanced diversification by a broadening of product breadth through technological advancements and investments in new specialty compounding assets. In addition, the Company will explore the mid-term monetization of its real estate holdings in an effort to build a state-of-the-art flagship rubber compounding facility while freeing up cash for inorganic growth. The new AMP segment will consolidate all operations which manufacture or distribute finished products to a variety of target markets including automotive, non-automotive and defense. AMP will continue to drive its own growth strategy while in parallel the Company undertakes an in-depth strategic review of all individual product lines this segment currently manufactures and sells, in order to assess their overall alignment with the new strategic direction of AirBoss. The Company will include supplemental unaudited information containing 8 quarters of historical financial information (from the first quarter of 2022 through the fourth quarter of 2023) for the two new reportable segments in its upcoming annual results. The supplemental historical business segment information will not represent a restatement or reissuance of previously issued financial statements and will relate entirely to segment presentation with no effect on previously reported consolidated results.

07:43 EST Marvell collaborates to deliver NTT DOCOMO OREX RAN solutions - Marvell Technology (MRLV) announced it has collaborated with leading companies to develop Open RAN solutions for use in NTT DOCOMO's OREX RAN infrastructure. Together, Marvell, Dell Technologies (DELL), Fujitsu and Wind River have combined critical silicon, system and software expertise to create Open RAN offerings that are commercially available to NTT DOCOMO and other carriers. Open RAN is set to account for 20-30% of worldwide RAN revenues by 2028, up from 7%-10% in 2024, according to a February 2024 report by Dell'Oro Group. "By working in a collaborative ecosystem, Marvell is helping raise the performance of Open RAN systems, striving for power, functionality and features on par with traditional 5G RAN systems," said Will Chu, senior vice president and general manager, Custom, Compute and Storage Group at Marvell. "The fourth generation of Marvell OCTEON 10 technology meets the demanding requirements of NTT DOCOMO's OREX RAN specifications. We're excited to move the Open RAN market forward alongside NTT DOCOMO, Dell Technologies, Fujitsu and Wind River."

07:42 EST Ascent Solar to fly space solar modules on NASA's LISA-T mission - Ascent Solar Technologies announced that the Company's solar module products will fly on NASA's upcoming Lightweight Integrated Solar Array and AnTenna mission, scheduled for launch this summer. The mission, led by NASA's Space Technology Mission Directorate and the agency's Marshall Space Flight Center in Huntsville, will demonstrate the capability to deploy large-area arrays on lightweight, low-cost and small spacecraft.

07:41 EST KeyCorp announces CAO Schosser to leave company, Gilbert to succeed - KeyCorp announced that Douglas Schosser, currently Chief Accounting Officer, CAO, will be leaving the company to pursue a senior executive position at another company, effective March 15, 2024. Stacy Gilbert will succeed him as KeyCorp's Chief Accounting Officer at that time. Gilbert has served as Corporate Controller of KeyCorp since August 2023. She previously served as Assistant Corporate Controller and Senior Director of External Reporting and Accounting Policy.

07:40 EST Hot Chili advances regional water supply opportunity - Hot Chili Limited reports that the Company has completed an initial concept study for a potential water supply business for the Huasco valley region of Chile. While Costa Fuego's mine development plan considers the use of raw seawater for future processing, the Water Supply Concept Study confirms potential to also develop a large, multi-user, desalination water supply business.

07:39 EST GE HealthCare, Biofourmis collaborate to extend patient monitoring - GE HealthCareand Biofourmis have announced a strategic collaboration aimed at enhancing continuity of care by enabling safe, effective, and accessible care in the home to support the patient journey beyond the hospital setting. The collaboration leverages the combined expertise of two market leaders to scale and deliver innovative care-at-home solutions. The goal of the GE HealthCare-Biofourmis collaboration is to enable more patients to go home earlier, and offer an alternative to facility-based care with the comfort and peace of mind that they are receiving high quality care at home with the intent of driving healthy behaviors in patients by managing them remotely. Moreover, insights from Biofourmis' FDA-cleared, AI-guided algorithms can help care teams deliver efficient, personalized care at home.

07:38 EST Alpha Metallurgical announces changes to board of directors - Per the company's corporate governance guidelines, director candidates may not stand for election beyond the age of 75 years. Having reached this age limit, Michael J. Quillen and Albert E. Ferrara, Jr. will not stand for election at the 2024 annual meeting of stockholders and will leave the board, effective before market open on Monday, February 26, 2024, after significant tenures. Ferrara, the company's longest-serving director, has served on the board since the company's formation in July 2016, while Quillen, who founded predecessor company Alpha Natural Resources in 2002, has served since November 2020. In addition, Elizabeth Fessenden, a director since February 2021, has elected to step down from the board, effective before market open on February 26, 2024. None of these departures is a result of disagreements with the company. In connection with these departures, the board has determined to reduce its size from nine directors to seven, effective February 26, 2024. Additionally, a new director, Shelly Lombard, has been appointed to join the board, effective at market close on February 26, 2024. Lombard has been appointed, effective upon joining the board, as chair of the audit committee. Gorzynski has been appointed lead independent director, effective February 26, 2024.

07:36 EST Uniti Group announces completion of ABS bridge facility, asset sales - Uniti Group announced that Uniti Fiber Bridge Borrower has entered into a Bridge Loan and Security Agreement for up to $350 million of borrowings pursuant to a multi-draw term loan facility. Borrowings under the Facility will bear interest at an initial rate equal to Term SOFR for the applicable interest period plus an applicable margin of 3.75%, subject to customary step-ups in the applicable margin based on how long the Facility remains outstanding. The ABS Borrower intends to cap Term SOFR for the duration of the Facility pursuant to an interest rate protection agreement. The Facility will mature 18 months from the initial draw date and is subject to customary covenants. The ABS Borrower intends to refinance the Facility in full with proceeds from a long-term ABS facility secured primarily by certain Uniti Fiber network assets. Barclays Bank PLC acted as sole structuring agent, lead left arranger and facility agent on the transaction. Deutsche Bank AG New York Branch and Citibank, N.A. acted as co-lead arrangers. Wilmington Trust, National Association is acting as administrative agent. Uniti also announced today multiple asset sales that it recently completed. First, Uniti sold its remaining investment interest in the fiber network operated by Bluebird Network LLC. In addition, Uniti sold to CableSouth Media III, the fiber and other network assets previously leased to SwyftFiber since its 2018 sale leaseback transaction with Uniti. As part of the agreement, Uniti will continue to have access to certain strands within the SwyftFiber network at zero-cost. Finally, Uniti recently completed the sale of essentially all of its remaining wireless towers to CTI Towers, Inc., a portfolio company of Palistar Capital LP. Total cash consideration for these transactions was approximately $87 million. For the twelve month period ending September 30, 2023, the aggregate reported revenue and Adjusted EBITDA associated with these asset sales were approximately $4 million and $9 million, respectively.

07:30 EST Allakos presents preclinical data on AK006 at AAAAI meeting - Allakos announced a poster presentation at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting. The poster highlights preclinical data detailing AK006's mechanism of action and ability to reduce MRGPRX2-induced skin inflammation. Inappropriate mast cell activation, via IgE-dependent and IgE-independent pathways, has been implicated in the pathogenesis of multiple inflammatory skin diseases. IgE-dependent mast cell activation has been identified as a pathogenic driver of chronic spontaneous urticaria and food allergy and agents which target this pathway have demonstrated therapeutic activity. More recently, mast cell activation through MRGPRX2, an IgE independent mast cell activation pathway, has been implicated in the pathogenesis of chronic spontaneous urticaria, atopic dermatitis and prurigo nodularis. AAAAI Presentation Details: The poster, titled: "MRGPRX2-Mediated Mast Cell Activation is a Shared Pathogenic Mechanism in Atopic Dermatitis and Prurigo Nodularis Patients that can be Inhibited by Siglec-6" was presented on Friday, February 23rd, key findings include: IgE-independent mast cell activation, via MRGPRX2, has been implicated in atopic dermatitis and prurigo nodularis disease pathogenesis Atopic dermatitis and prurigo nodularis skin lesions contain mast cells displaying signs of MRGPRX2 activation, as well as elevated and activated macrophages AK006 has a dual mechanism of action that inhibits mast cells and reduces mast cells via antibody dependent cellular phagocytosis in the presence of activated macrophages; In an MRGPRX2-induced skin inflammation model, AK006 reduced skin inflammation and reduced mast cells numbers via ADCP; By broadly inhibiting and reducing mast cells, AK006 has the potential to treat inflammatory skin diseases, such as atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria. The data presented Friday add to previous published preclinical data demonstrating that AK006 inhibits both IgE-dependent and IgE-independent mast cell activation and can reduce mast cell numbers at sites of inflammation where activated macrophages are found.

07:25 EST Genius Group expands AI-powered Genius University - Genius Group announced the launch of a series of new initiaves to expand its AI-Powered Genius University. Targeted at both university students and entrepreneurial leaders seeking to reskill themselves in the age of artificial intelligence, these initiatives include: Expansion to over 50 AI tools for students on its Student AI platform to over 50 AI Tools and AI Tutors, including 'Personal Statement Writer', 'Essay Summarizer' 'APA reference convertor', MLA reference writer', 'Math Problem Solver', 'Coding Helper' and a wide range of other AI Tools requested by students. The launch of AI Avatar C-Suite Teams, giving entrepreneurs and enterprises over 30 AI avatars to choose from to build their own AI advisory board or expert panel, ranging from Albert Einstein, Leonardo Da Vinci and George Washington to Marie Curie, Cleopatra and Mother Theresa - Each AI avatar having their own specific knowledge base, intelligence and perspective based on each unique character. Growth of Genius University's Genius Apprentice Program and Scholarship Program, linking university students with entrepreneurs and their companies for work experience, with student-staff teams working together on AI projects via Genius Group's AI Courses, hosted on Genius Group's AI-driven Edtech platform, GeniusU.

07:23 EST Microbix Biosystems announces issuance of stock options - Microbix Biosystems announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. In consultation with management, Microbix's Board of Directors has approved the issuance of 2,795,000 options in accordance with the terms of the Stock Option Plan. The approved options are exercisable at a price of $0.40 per share, as determined by the closing price of the TSX on 22 February, 2024. Each option will vest and be exercisable after three years and have a total life of five years. The stock option grants form part of the total remuneration package for the recipients and are subject to TSX approval.

07:22 EST Interactive Strength enters distribution agreement with WOODWAY - Interactive Strength has entered into an exclusive worldwide distribution agreement with WOODWAY USA, which grants the right for WOODWAY to sell and distribute the Company's CLMBR product anywhere in the world in the commercial market. As part of the agreement, WOODWAY is placing an initial purchase order for 2,150 units, which is expected to generate more than $7 million in net revenue for TRNR and anchors the Company's guidance that it expects to generate net revenue of between $15 million and $20 million in 2024. The agreement has an initial term of five years, but there are extensions included as this relationship is expected to be long-term. In order for WOODWAY to share more in the value creation of this agreement and as a way to create additional alignment between the parties, the Company has issued 800,000 warrants to WOODWAY with an exercise price of $1.25 per share.

07:19 EST Skye Bioscience completes enrollment of Phase 2a trial of SBI-100 - Skye Bioscience has dosed 56 patients using SBI-100 Ophthalmic Emulsion in its Phase 2a study and completed final study visits for all patients. SBI-100 OE is a cannabinoid receptor type 1 agonist administered topically onto the eye and is being developed to address unmet needs of patients with elevated intraocular pressure related to primary open-angle glaucoma or ocular hypertension. All treated patients completed the study, with no early discontinuations due to adverse events. Topline data for the entire study will be available in Q2.

07:17 EST American Lithium files PEA for Falchani hard rock lithium project - American Lithium announced it has filed an independent National Instrument 43-101 Technical Report on the Preliminary Economic Assessment for the Falchani Lithium Project located in Puno, southwestern Peru Highlights of the PEA were previously announced on January 10, 2024. "We are very pleased to have filed this updated PEA on Falchani, which shows very robust economics for this large-scale, high purity, hard rock project," stated Simon Clarke, CEO of American Lithium. "This is a major milestone in the process to complete pre-feasibility and move the Project into mine permitting. The filing of the Semi-Detailed Environmental Impact Assessment late last year also positions the Project to be fast-tracked. Falchani has demonstrated the potential for long life, high annual production, with one of the lowest operating cost profiles globally for developers."

07:17 EST Voyager Therapeutics reports selection of gene therapy development candidate - Voyager Therapeutics (VYGR) announced that the joint steering committee with its collaborator Neurocrine Biosciences (NBIX) has selected a lead development candidate in the Friedreich's ataxia program. The candidate combines a frataxin gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager's TRACER capsid discovery platform. The companies expect the program to advance into first-in-human clinical trials in 2025. Selection of the development candidate triggered a $5M milestone payment to Voyager, which the company expects to receive in the first quarter of 2024. Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program. "The nomination of this development candidate in FA marks an important step in our strategic collaboration with Neurocrine, reflecting the power of combining Voyager's TRACER AAV capsids and payload design capabilities with Neurocrine's expertise in neuroscience and clinical development," said Alfred W. Sandrock, Jr., M.D., Ph.D., CEO of Voyager. "While there has been encouraging recent progress in the treatment of FA, it remains a very challenging and eventually fatal disease for which new therapeutic approaches are needed. We believe our strategy to replace the defective frataxin gene could address the underlying disease etiology of FA. We look forward to progressing this and our other gene therapy programs, including our wholly-owned SOD1 ALS program and our Neurocrine-partnered GBA1 Parkinson's program, towards clinical studies."

07:14 EST SK Telecom, Deutsche Telekom, Softbank, others to establish joint venture - SK Telecom (SKM), Deutsche Telekom (DTEGY), e& Group, Singtel and SoftBank (SFTBY) held the inaugural meeting of the Global Telco AI Alliance, GTAA, at MWC Barcelona 2024 and announced their plans to establish a joint venture. Through the Joint Venture Company, the five companies plan to develop Large Language Models specifically tailored to the needs of telecommunications companies. The LLMs will be designed to help telcos improve their customer interactions via digital assistants and chatbots. The goal is to develop multilingual LLMs optimized for languages including Korean, English, German, Arabic and Japanese, with plans for additional languages to be agreed among the founding members.

07:12 EST Teva, Jiangsu Nhwa Pharmaceutical enter partnership - Teva Pharmaceutical Investments Singapore, or TPIS, a subsidiary of Teva, and Jiangsu Nhwa Pharmaceutical announced it formed a partnership for the marketing and distribution of Teva's Austedo for the treatment of neurodegenerative and movement disorders - chorea associated with Huntington's disease, or HD, and tardive dyskinesia, or TD, in adults. The partnership intends to increase patients' access to Teva's Austedo, leveraging Nhwa's leadership in China's neuro-psychiatric health sector.

07:11 EST Marimaca Copper announces 2024 regional exploration strategy - Marimaca Copper announced its regional exploration strategy for 2024. Following a comprehensive review and reinterpretation of historical geological information, the Company's regional priority for 2024 will be further exploration at the Sierra de Medina property block, located approximately 25km from the Marimaca Oxide Deposit. The Company believes that the property position has discovery potential in an emerging belt of large scale manto-type copper deposits in the Chilean Coastal Cordillera. SdM, along with the Marimaca-type satellite discoveries made in 2021 including Mercedes, provide an organic exploration pipeline for Marimaca, which will be evaluated in parallel with the development of the MOD. Highlights: Full geological review completed of Marimaca's ~66,300ha land position in the Chilean coastal copper belt, with a focus on historical information available at various targets across the SdM property block; Marimaca established as a core land holder in the emerging discovery belt between Capstone's Mantos Blancos operation and Antofagasta Minerals' new Cachorro discovery; Presence of key regional mineralized units across the SdM property block confirmed via historic drilling and surface geology: Results from Marimaca's early 2024 surface sampling program identified a ~4km surface geochemical anomaly at the Pias Target, which is supported by historical shallow drilling completed at the target: 32m at 2.36% Cu from surface in hole SHP-03; 30m at 1.69% CuT from 2m, including 12m at 3.97% CuT from 2m in hole SFP-02; 30m at 1.05% Cu from surface in hole SHP-04; 14m at 2.54% Cu from 2m in hole SHP-15; 16m at 1.84% Cu from 2m in hole SHP-17; Historic drilling at Pias was completed to an average depth of 68m without testing deeper volcanic and sedimentary units known to be regionally productive; Recent regional discoveries demonstrate mineralization hosted dominantly in the underlying lower sedimentary and volcanic units which provides a model for future exploration drilling at depth at Pias; Outcropping mineralized sediments at the Antena target confirmed via surface mapping; Mineralized volcanic and sedimentary units confirmed in southern areas of the SdM claim block, indicating continuity and regional extent of key productive units for copper mineralization. The Company is currently considering funding options for additional work at the SdM property block, including partnership and joint-venture opportunities. Initial work plan would include geological mapping, resistivity and high-resolution drone-mounted magnetics geophysics, followed by additional surface geochemistry to refine key targets for initial drilling.

07:09 EST Metalla Royalty & Streaming provides update for Gosselin, 2024 catalysts - Metalla Royalty & Streaming reports the 2024 portfolio catalysts and the updated Mineral Resource estimates for Gosselin, where Metalla holds a 1.35% Net Smelter Return royalty that covers the northern portion of Cote and 100% of the Gosselin deposit. Brett Heath, President & CEO of Metalla commented, "Gosselin continues to show that it has potential to become a very significant asset. In 2023 we saw an increase of 2.4 million ounces from 57 diamond drill holes totaling 34,790 meters. Gosselin stands as a substantial deposit on its own with 7.4 million ounces. Combined with Cote, they host an estimated Measured and Indicated Mineral Resource of 16.5 million ounces, and an additional 4.2 million ounces of Inferred resources. This places the project in an elite league among global gold mines of large scale. In the upcoming year, IAMGOLD indicated that it will focus on further exploration with a 35,000-meter drill hole program at Gosselin, aiming to probe potential extensions of the breccias between resource pits, as well as delving deeper beneath the mineralized envelopes to ascertain the full extent of these promising deposits."

07:08 EST Hot Chili announces another resource increase for Costa Fuego project - Hot Chili Limited announces another Resource increase for its Costa Fuego copper-gold project, located in the coastal range, 600 km north of Santiago, Chile. The MRE update follows 24 months of material investment, totalling 24.5 km of drilling across Costa Fuego; a mix of development, metallurgical, geotechnical, resource expansion and exploration drilling, designed to progress the Costa Fuego project towards its Pre-feasibility Study expected in H2 2024.

07:06 EST First Mining Gold provides update on temporary winter road - First Mining Gold announces that it has received construction permits for a temporary winter road to the Springpole Gold Project exploration camp site by the Ontario Ministry of Natural Resources and Forestry on February 9, 2024, which would allow for the safe transport of supplies and people overland. "Warm winter conditions are impacting all who live and operate in the north," stated Dan Wilton, CEO of First Mining. "This Temporary Winter Road will allow First Mining to keep its focus on operating in a safe and environmentally responsible manner."

07:05 EST EnCore Energy completes $70M transaction with Boss Energy - enCore Energy (EU) announced the completion of the transactions under the Master Transaction Agreement with Boss Energy Limited (BQSSF), headlined by the sale of a 30% ownership interest in enCore's Alta Mesa project to Boss Energy for $60M, and including an investment of $10M into enCore common shares by Boss Energy. The Transaction provides enCore with the financial capacity to significantly accelerate its uranium production pipeline across South Texas through the development of multiple satellite operations. Transaction Highlights: enCore received US$60 million in full payment for Boss Energy's 30% share of the JV; enCore received an additional US$10 million from Boss Energy as payment for a private placement of 2,564,102 enCore shares; The formation of a joint venture company owning Alta Mesa with enCore holding a 70% joint venture interest and remaining the project manager, and Boss Energy holding a 30% joint venture interest.

07:04 EST STMicroelectronics, Renesas, Ac6 join the Zephyr Project - The Zephyr Project announced that Renesas Electronics (RNECY), STMicroelectronics (STM), and Ac6 have joined as Silver members. Zephyr, an open source project at the Linux Foundation that builds a secure, connected and flexible RTOS for future-proof and resource-constrained devices, is easy to deploy and manage. It is a proven RTOS ecosystem created by developers for developers. The Zephyr 3.6 release is a significant step towards delivering the next Long-Term Support version of the project later this year. It includes several security-focused features such as the integration of TF-M 2.0, and improved tooling for SBOM generation. With over 30 new boards added across the entire range of supported architectures, Zephyr now supports over 600 boards that developers can readily use to build their embedded applications.

06:59 EST Azimut Exploration appoints Vanessa Laplante to board - Azimut Exploration announced the voting results for its Annual General Meeting of shareholders held February 23, 2024. At the Meeting, Mrs. Vanessa Laplante was elected as a director to join the Board and the Company anticipates the valuable contribution she will bring. The Board of Directors also wishes to acknowledge the remarkable participation and commitment to the Company by Mrs. Angelina Mehta, who did not stand for reappointment.

06:58 EST Aecom selected to deliver design services for Ontario Line - AECOM will provide design services as part of the Pape North Connect Team selected by Infrastructure Ontario and Metrolinx to deliver the Pape Tunnel and Underground Stations contract for the Ontario Line, a 15.6-kilometer stand-alone rapid transit line that is expected to improve access and reduce daily travel time for Toronto commuters. The PTUS contract is being procured under a Development and Master Construction Agreement with Metrolinx. The DMCA incorporates a multi-stage design process called the development phase that allows for a collaborative approach between Metrolinx and Pape North Connect to finalize the scope, risk allocation and pricing of various contract elements. Pape North Connect is a consortium of AECOM, Arcadis, Webuild Civil Work Inc., and Fomento de Construcciones y Contratas Canada Ltd.

06:56 EST Playtika exploring opportunities to enhance shareholder return - Exploring other opportunities to enhance shareholder return, including a share repurchase program in the future.

06:55 EST Playtika initiates quarterly dividend of 10c per share - Initiating a quarterly dividend of $0.10 per share, with future dividends subject to market conditions and Board approval.

06:49 EST Dundee Precious Metals announces new results from Coka Rakita programs - Dundee Precious Metals reported new assay results from its ongoing infill drilling program at Coka Rakita in eastern Serbia, where DPM recently announced an Inferred mineral resource estimate of 1.8 million ounces of gold. The company also reported results from the scout drilling program at the Dumitru Potok and Frasen prospects, which are located on the Coka Rakita licence and are approximately 1.0 to 1.5 kilometres north of the Coka Rakita deposit.

06:48 EST AstraZeneca says Voydeya recommended for approval in the EU by CHMP - Voydeya has been recommended for marketing authorisation in the European Union as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria, or PNH, who have residual haemolytic anaemia, AstraZeneca announced. The Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency based its positive opinion on results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology. Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris or Soliris to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant extravascular haemolysis, or EVH, while treated with a C5 inhibitor.

06:42 EST Calibre Mining announces drill results from program at Limon Mine Complex - Calibre Mining announced drill results from its 2023 resource expansion and infill program at the Tigra, Limon Norte and Pozo Bono open pit deposits located next to the Limon processing plant. These high-grade intercepts combined with the recent positive news from the Panteon VTEM Gold Corridor, demonstrate that the entire Limon district remains open for expansion and discovery. Drill intercept highlights from the Tigra, Limon Norte and Pozo Bono targets include: 68.72 g/t Au over 2.0 metres Estimated True Width and 16.49 g/t Au over 5.9 metres ETW including 26.71 g/t Au over 3.5 metres ETW in Hole LIM-23-4875; 18.68 g/t Au over 5.9 metres ETW including 55.68 g/t Au over 2.0 metres ETW in Hole LIM-23-4876; 9.26 g/t Au over 5.0 metres ETW including 17.10 g/t Au over 2.6 metres ETW in Hole LIM-23-4858; 12.85 g/t Au over 4.2 metres ETW including 14.00 g/t Au over 3.8 metres ETW in Hole LIM-23-4793; 11.91 g/t Au over 3.1 metres ETW including 15.22 g/t Au over 2.2 metres ETW in Hole LIM-23-4798; 8.95 g/t Au over 11.3 metres ETW including 21.96 g/t Au over 4.2 metres ETW in Hole LIM-23-4812; 7.36 g/t Au over 8.4 metres ETW including 11.80 g/t Au over 4.9 metres ETW in Hole LIM-23-4805. Darren Hall, President and CEO of Calibre, stated: "I am excited by these exceptionally high-grade drill results from numerous targets at our Limon Gold Mine. Drilling efforts have not only instilled confidence at the yet-to-be-developed Pozo Bono open pit project but have also identified underground potential along the Limon trend. These results, coupled with the continuous high-grade drill results from the Panteon VTEM Gold Corridor, put us in a solid position to replace reserves for year-end 2023. The Limon district has produced over 4.5 million ounces of gold, and continues to demonstrate its significant value, reinforcing our confidence that resource conversion and high-grade additions will drive production and extend mine life. With multiple rigs active, 2024 is proving to be another exciting and productive year, with drilling operations underway at numerous targets. The Valentine Gold Mine construction team remains focused, with overall progress at 55% and on track for production in H1 2025. SAG and ball mill motors arrived into Newfoundland on February 21, and the mills are scheduled to arrive in the next few days."

06:37 EST Capcom announces $1M grand prize for Capcom Pro Tour 2024 - Capcom will offer $1M as the grand prize for Capcom Pro Tour 2024, its series of esports tournaments held worldwide that feature the company's storied Street Fighter series. Capcom has held the Capcom Pro Tour along with the world-championship tournament Capcom Cup each year since 2014, staging live competitions in more than 40 countries while carrying out online events in as many as 129 countries worldwide. Additionally, Capcom runs the competitive team-based Street Fighter League in Japan, the U.S.A., and Europe.

06:35 EST Jaguar Mining reports updated mineral reserves, resources - Jaguar Mining announced its annual Mineral Reserves and Mineral Resources statement for 2023. Proven and Probable Mineral Reserves and Measured, Indicated and Inferred Mineral Resources figures are reported for Jaguar's two operating mining and production complexes, Turmalina and Caete, and for the Paciencia Complex, currently on care and maintenance. The Turmalina Complex is comprised of the Turmalina mine, the Faina and Oncas de Pitangui growth projects as well as the Zona Basal and Pontal deposits. The Caete Complex is comprised of the Pilar mine, the Roca Grande mine and the Corrego Brandao deposit. The Paciencia Complex is comprised of the Santa Isabel and Margazao mines and the Bahu deposit. HIGHLIGHTS: Consolidated Proven and Probable Mineral Reserves show additions of 132 koz reflecting the addition of reserves at the Faina project, offset by mined depletion at Pilar and Turmalina of 88 koz and removal of remnant material from inventory at Turmalina of 28 koz for a net increase of 4% to 470 koz, Faina Probable Mineral Reserves added 132 koz to Jaguar's 2P Mineral Reserves inventory. Consolidated Measured and Indicated Mineral Resources increased by 27% to 1,676 koz, reflecting the addition of measured and indicated mineral resources from the Oncas de Pitangui project. Oncas de Pitangui Indicated Mineral Resources added 448 koz, to Jaguar's Mineral Resources inventory. Consolidated Inferred Mineral Resources increased by 41% to 1,628 koz driven by the addition of inferred mineral resources from the Oncas de Pitangui project. Oncas de Pitangui Inferred Mineral Resources added 379 koz to the Company's inventory. Life of Mine plans at the Pilar operation forecast production at current rates into 2028. At the Turmalina Complex, with Faina ramping up from this year through 2026, the LOM extends at increased production rates beyond 2030. The Company continues to progress project work required to support the publication of initial mineral reserves for the Oncas de Pitangui project in the fourth quarter of 2024. Vern Baker, CEO of Jaguar Mining stated, " This year's Mineral Reserve and Mineral Resource update further advances our organic growth strategy, especially with the initial disclosure of probable Mineral Reserves from our Faina project and the addition of 800 koz of Mineral Resources added from the acquisition of Iamgold's Sao Sebastiao deposit and Oncas de Pitangui project . A net increase of 4% in Mineral Reserves along with the material increases in Mineral Resources is a very positive driver underpinning the long-term future of the company.

06:33 EST Clean Energy opens two RNG fueling stations in DFW area - Clean Energy Fuels announced the opening of two new fueling stations that offer heavy-duty truck and other fleet vehicles renewable natural gas. A station in North Fort Worth, near Alliance and DFW airports, and another in South Dallas close to I-45, I-35 and I-20, are strategically located near dozens of distribution centers and allow trucks to take advantage of a fuel that provides similar convenience as diesel, yet is rated as one of the cleanest in the world. The two stations expand Clean Energy's fueling network of over 600 stations, and open at a time when RNG is becoming a fuel that many fleets are embracing to meet their carbon emissions reduction goals. A new 15-liter natural gas engine for heavy-duty trucks, the Cummins' X15N, is anticipated to be commercially available later in 2024 and is currently being tested by some of the largest and most demanding fleets in the country, including Walmart, Werner, Knight Swift, FedEx Freight and UPS. The early reaction to the X15N has been positive at a time when the heavy-duty truck market continues to struggle to find affordable and reliable alternatives to decarbonize their fleets.

06:22 EST Radware announces new flexible business model for MSSPs - Radware announced a new flexible business model for managed security service providers. The offering enables service providers to enjoy new revenue streams and grow their businesses by extending an innovative line of managed network and application security services to their customers. Catering to their business needs, Radware's new offering enables MSSPs to customize, rebrand, and resell the company's Cloud DDoS Protection and Cloud Application Protection Services. The services are built to defend MSSPs' customers against advanced cyber threats, including DDoS, DNS, application, and layer 7 Web DDoS attacks.

06:20 EST Fresh Del Monte raises quarterly dividend to 25c per share - The Company's Board of Directors declared on February 23, 2024, an increase to the quarterly cash dividend to $0.25 per share, payable on March 29, 2024, to shareholders of record on March 7, 2024.

06:16 EST Tower Semiconductor, Tianyi Micro collaborate to develop OLED microdisplays - Tower Semiconductor and Tianyi Micro announced their strategic cooperation in the development of next-generation OLED micro displays for AR/VR, addressing the growing Chinese and global market needs for advanced AR/VR solutions. The development is based on Tower's unique 180nm and 65nm dedicated micro display backplane process flows, supporting current-driven OLED pixel designs.

06:14 EST Wipro announces joint private wireless solution with Nokia - Wipro (WIT) announced a joint private wireless solution with Nokia (NOK), to help enterprises scale their digital transformation. This joint solution will provide enterprises with a more secure 5G private wireless network solution integrated with their operation infrastructure. Nokia will provide the Nokia Digital Automation Cloud, or DAC, and Modular Private Wireless, or MPW, solutions inclusive of hardware and software. Wipro, with its 5G Def-i with Industry DOT and OTNxt platforms, will offer strategic guidance and industry insights for effective integration into the enterprise environment. Wipro will develop the architecture and design.

06:10 EST Faraday Future to implement 1-for-3 reverse stock split - Faraday Future announced that the company intends to implement a reverse stock split of the issued and outstanding shares of the company's common stock, par value $0.0001 per share, at a ratio of 1-for-3, that is expected to become effective at 5:00 p.m. ET on February 29. The company's common stock is expected to begin trading on a split-adjusted basis commencing upon market open on March 1.

06:02 EST ServiceNow, Nvidia broaden pact with telco-specific generative AI solutions - ServiceNow (NOW) and Nvidia (NVDA) announced that they are broadening their relationship with the introduction of telco-specific generative AI solutions to elevate service experiences. The first solution, Now Assist for Telecommunications Service Management, or TSM, is built on the Now Platform and uses Nvidia AI to help boost agent productivity, speed time to resolution, and enhance customer experiences. As telcos look to reduce costs and uncover new business opportunities, they're turning to AI and automation. In a survey from IDC, 73% of global telecommunications service providers identified AI/ML investments to support operations as their top transformation priority.

05:58 EST Cisco, Telus International launch new 5G capabilities in North America - Cisco and Telus announced they are launching new 5G capabilities in North America to serve IoT use cases across industry verticals, with a focus on connected cars. The network will serve as a foundation to support drive testing by a major North American automotive manufacturer's 5G Connected Car, while setting the stage for enhanced experiences for customers and revenue opportunities for carmakers. With these enhanced capabilities, Telus Control Center powered by Cisco can now support automated provisioning, dynamic policy, charging and quota management outcomes to launch new subscription services on demand, and manage SIM and vehicle lifecycle for any Connected Car OEM or enterprise.

05:53 EST Verizon, KDDI partner to connect Afeela electric vehicles - Verizon (VZ) and KDDI announced plans for a collaboration to bring connected car capabilities to the Afeela brand's first mass-production electric vehicle in the United States. This collaboration will enable cellular connectivity and advanced mobility features for the first Afeela mass-produced electric vehicle in the United States, using Verizon's 5G and 4G LTE networks and KDDI's Global Communications Platform to support Car Connectivity. Sony Honda Mobility was established by Sony (SONY) and Honda (HMC) for the joint development and sale of electric vehicles and the provision of services for mobility in September 2022. Under the purpose of "Move people, through the pursuit of innovation with diverse inspirations," SHM is paving the way for a new era of mobility as a Mobility Tech Company.

05:30 EST Warner Music signs Nora Fatehi to U.S. deal - Nora Fatehi, the singer, dancer, and actress, whose music has already attracted millions of fans and billions of views and streams, has signed a new deal with Warner Music - her first agreement with a major global record company. The partnership is to promote Nora's global music career, working with teams in the U.S. and across the world, expanding her fanbase through a range of exciting projects and releases. She will remain signed to T-Series, the Indian music label and movie studio, for her Bollywood projects.

05:23 EST Elbit Systems awarded $600M contract to supply systems - Elbit Systems announced, following its announcement from August 16, 2023, that it was awarded a contract worth approximately $600M to supply systems to Hanwha Defense Australia for the Australian Land 400 Phase 3 Project. This project aims to deliver advanced protection, fighting capabilities and sensors suite to the Redback Infantry Fighting Vehicles, or IFV, for the Australian Army. The contract will be performed over a period of five years.

05:08 EST Nio enters technology license agreement with Forseven - Nio announced that its subsidiary, Nio Technology, has entered into a technology license agreement with Forseven, a subsidiary of CYVN Holdings. Pursuant to the technology license agreement, the company will grant a non-exclusive and non-transferrable worldwide license to Forseven to use certain of the company's existing and future technical information, technical solutions, software and intellectual property rights related to or subsisting in the company's smart electric vehicle platforms for the research and development, manufacturing, sales, import and export of vehicle models sold or marketed under Forseven brand(s) meeting pre-agreed manufacturer's suggested retail price thresholds under the technology license agreement, and the provision or procurement of certain after-sales services for the licensed products to its users. Under the technology license agreement, the company will receive technology license fees comprising a non-refundable, fixed upfront license fee plus royalties determined based on the future sales of licensed products by Forseven. Unless terminated in accordance with provisions provided therein, the technology license agreement will remain valid until the end of production of the licensed products or the expiration of Forseven's obligation to provide after-sales services to its users. The technology license agreement may be terminated by either party under certain conditions. The company may also terminate the technology license agreement under certain conditions, including if a company that owns one or more automotive brands and sells vehicles under such brand(s) to the market obtains control of Forseven.